1
|
Tahara Y, Hashimoto A, Owa H, Ono T, Kuroda N, Aoki M, Fuke H, Kawabata H, Wakita Y, Shimizu A. [A case of aortic thrombus during chemotherapy for esophageal cancer]. Nihon Shokakibyo Gakkai Zasshi 2024; 121:212-220. [PMID: 38462469 DOI: 10.11405/nisshoshi.121.212] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 03/12/2024]
Abstract
A 59-year-old man presented to our hospital with a chief complaint of epigastric pain. Pertinent history included a distal gastrectomy for gastric cancer and alcohol dependence. He underwent contrast-enhanced computed tomography (CT) and esophagogastroduodenoscopy, which led to a diagnosis of esophageal cancer (cT2N2M1, stage IVb). Subsequently, he underwent chemotherapy using 5-fluorouracil and cis-diamminedichloroplatinum and radiotherapy. A total of 44 days after treatment initiation, the patient experienced nausea and hepatobiliary enzyme elevation. CT and abdominal ultrasonography were performed, and he was diagnosed with an abdominal aortic thrombus. Intravenous heparin was administered as an anticoagulant therapy. Twenty-two days after treatment initiation, the thrombus was no longer visible on abdominal ultrasonography. The patient was then treated with warfarin. It cannot be ruled out that the patient's hepatobiliary enzyme elevation was induced by the anticancer drugs. However, enzyme elevation improved with the disappearance of the abdominal aortic thrombus, suggesting that the aortic thrombus may have contributed to the hepatobiliary enzyme elevation. No thrombus recurrence was observed until the patient's death after an initial treatment with antithrombotic agents. This case indicates that malignant tumors and chemotherapy can cause aortic thrombi, and thus, care should be exercised in monitoring this potential complication.
Collapse
Affiliation(s)
- Yuichi Tahara
- Department of Internal Medicine, Saiseikai Matsusaka General Hospital
| | - Akira Hashimoto
- Department of Internal Medicine, Saiseikai Matsusaka General Hospital
| | - Hirono Owa
- Department of Internal Medicine, Saiseikai Matsusaka General Hospital
| | - Takahiro Ono
- Department of Internal Medicine, Saiseikai Matsusaka General Hospital
| | - Naoki Kuroda
- Department of Internal Medicine, Saiseikai Matsusaka General Hospital
| | - Masatoshi Aoki
- Department of Internal Medicine, Saiseikai Matsusaka General Hospital
| | - Hiroyuki Fuke
- Department of Internal Medicine, Saiseikai Matsusaka General Hospital
| | - Hiroyuki Kawabata
- Department of Internal Medicine, Saiseikai Matsusaka General Hospital
| | - Yoshihiro Wakita
- Department of Internal Medicine, Saiseikai Matsusaka General Hospital
| | - Atsuya Shimizu
- Department of Internal Medicine, Saiseikai Matsusaka General Hospital
| |
Collapse
|
2
|
Hamada Y, Tanaka K, Mukai K, Baba Y, Kobayashi M, Tominaga S, Kawabata H, Sawai S, Kaneko M, Sugimoto S, Inoue H, Mimuro M, Tamaru S, Nakagawa H. Efficacy of Endoscopic Resection for Rectal Neuroendocrine Tumors Smaller than 15 mm. Dig Dis Sci 2023:10.1007/s10620-023-07914-4. [PMID: 37024740 DOI: 10.1007/s10620-023-07914-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/29/2022] [Accepted: 03/02/2023] [Indexed: 04/08/2023]
Abstract
BACKGROUND Local resection, including endoscopic resection, is recommended for rectal neuroendocrine tumors (NETs) < 15 mm in patients without risk factors for metastasis, though the short- and long-term outcomes are unclear. AIMS This study investigates the efficacy of endoscopic resection for rectal NETs < 15 mm. METHODS The short- and long-term outcomes of patients with rectal NETs < 15 mm who underwent endoscopic resection and the outcomes of each endoscopic technique were analyzed. The tumors were stratified as < 10 mm (small-size group, SSG) and 10-14 mm (intermediate-size group, IMG). RESULTS Overall, 139 lesions (SSG, n = 118; IMG, n = 21) were analyzed. All tumors were classified as G1 (n = 135) or G2 (n = 4) according to the 2019 World Health Organization grading criteria. The complete resection rate was not different between the groups (P = 0.151). Endoscopic submucosal dissection (ESD) and endoscopic submucosal resection with a ligation device (ESMR-L) achieved complete resection rates > 90% in the SSG. The ESMR-L procedure time (P < 0.001) and hospitalized period (P < 0.001) were significantly shorter than those of ESD. ESD achieved a complete resection rate of 80.0% in the IMG. The tumor size did not affect the overall survival or rate of lymph node/distant metastases. CONCLUSIONS Endoscopic resection is a feasible and effective treatment for patients with rectal NETs < 15 mm without the risk factors of metastasis. ESMR-L and ESD are optimal techniques for resecting tumors smaller than 10 mm and 10-14 mm, respectively.
Collapse
Affiliation(s)
- Yasuhiko Hamada
- Department of Gastroenterology and Hepatology, Mie University Hospital, 2-174 Edobashi, Tsu, Mie, 514-8507, Japan
| | - Kyosuke Tanaka
- Department of Gastroenterology and Hepatology, Mie University Hospital, 2-174 Edobashi, Tsu, Mie, 514-8507, Japan.
- Department of Endoscopy, Mie University Hospital, Tsu, Japan.
| | - Katsumi Mukai
- Department of Gastroenterology, Suzuka General Hospital, Suzuka, Japan
| | - Youichirou Baba
- Department of Pathology, Suzuka General Hospital, Suzuka, Japan
| | - Makoto Kobayashi
- Department of Gastroenterology, Municipal Yokkaichi Hospital, Yokkaichi, Japan
| | - Shintaro Tominaga
- Department of Gastroenterology, Municipal Yokkaichi Hospital, Yokkaichi, Japan
| | - Hiroyuki Kawabata
- Department of Gastroenterology, Saiseikai Mastusaka General Hospital, Matsusaka, Japan
| | - Shoma Sawai
- Department of Gastroenterology, Saiseikai Mastusaka General Hospital, Matsusaka, Japan
| | - Masabumi Kaneko
- Department of Gastroenterology, Matsusaka General Hospital, Matsusaka, Japan
| | - Shinya Sugimoto
- Department of Gastroenterology, Ise Red Cross Hospital, Ise, Japan
| | - Hidekazu Inoue
- Department of Gastroenterology, Mie Prefectural Medical Center, Yokkaichi, Japan
| | - Maya Mimuro
- Department of Oncologic Pathology, Mie University Hospital, Tsu, Japan
| | - Satoshi Tamaru
- Department of Clinical Research Center, Mie University Hospital, Tsu, Japan
| | - Hayato Nakagawa
- Department of Gastroenterology and Hepatology, Mie University Hospital, 2-174 Edobashi, Tsu, Mie, 514-8507, Japan
| |
Collapse
|
3
|
Hara F, Ono M, Kitano S, Nakayama T, Kawabata H, Watanabe K, Sasaki K, Kataoka T, Saji S, Yonemori K, Shien T, Iwata H. 160TiP A randomized controlled phase III study of bevacizumab and paclitaxel in combination with atezolizumab as a treatment for patients with locally advanced or metastatic hormone receptor-positive HER2-negative breast cancer: JCOG1919E/AMBITION study. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.03.178] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
|
4
|
Sugimoto S, Hattori A, Maegawa Y, Nakamura H, Okuda N, Takeuchi T, Oyamada J, Kamei A, Kawabata H, Aoki M, Naota H. Long-term Outcomes of Therapeutic Endoscopic Retrograde Cholangiopancreatography for Choledocholithiasis in Patients ≥90 Years Old: A Multicenter Retrospective Study. Intern Med 2021; 60:1989-1997. [PMID: 33551408 PMCID: PMC8313914 DOI: 10.2169/internalmedicine.6478-20] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/09/2020] [Accepted: 12/16/2020] [Indexed: 12/27/2022] Open
Abstract
Objective The safety and prognosis of complete stone removal for the treatment of choledocholithiasis in older patients are unknown. This multicenter retrospective study assessed the outcomes of complete stone removal in elderly patients (≥90 years) with respect to the prognosis. Methods We divided patients who underwent endoscopic cholangiopancreatography for choledocholithiasis into two groups: complete stone removal or incomplete stone removal with plastic stent insertion. The patient characteristics, adverse events, number of endoscopic cholangiopancreatographies, overall survival rates, and disease-specific cumulative death were compared between the groups. Patients Two hundred and twenty-three participants ≥90 years old were included in the study, including 48 (22%) men and 175 (78%) women. The median age was 92 (range, 90-104) years old. There were 160 (72%) and 63 (28%) patients in the complete and incomplete groups, respectively. Results The age, performance status, comorbidities, severe complication rates, and stone diameter were comparable between the groups. The proportion of patients with at least 5 stones was significantly higher in the incomplete group than in the complete group [complete group: 8.1% (13/160) and incomplete group: 21% (13/63), p<0.01]. The overall survival rate was significantly higher in the complete group (p<0.01), while the disease-specific cumulative death rate was higher in the incomplete group (p<0.01). Conclusion Complete stone removal for choledocholithiasis may contribute to a better prognosis in elderly patients ≥90 years old.
Collapse
Affiliation(s)
| | - Aiji Hattori
- Division of Gastroenterology, Saiseikai Matsusaka General Hospital, Japan
| | - Yuri Maegawa
- Division of Gastroenterology, Matsusaka Chuo General Hospital, Japan
| | | | - Naoko Okuda
- Division of Gastroenterology, Ise Red Cross Hospital, Japan
| | | | - Jun Oyamada
- Division of Gastroenterology, Ise Red Cross Hospital, Japan
| | - Akira Kamei
- Division of Gastroenterology, Ise Red Cross Hospital, Japan
| | - Hiroyuki Kawabata
- Division of Gastroenterology, Saiseikai Matsusaka General Hospital, Japan
| | - Masatoshi Aoki
- Division of Gastroenterology, Saiseikai Matsusaka General Hospital, Japan
| | - Hiroaki Naota
- Division of Gastroenterology, Matsusaka Chuo General Hospital, Japan
| |
Collapse
|
5
|
Abstract
Hereditary hemorrhagic telangiectasia (HHT) is a rare disorder characterized by telangiectasias and arteriovenous malformations (AVMs), which can involve multiple organ systems. Although hepatic involvement is common, the development of portosystemic encephalopathy is extremely rare. We herein report a 72-year-old woman with HHT-induced portosystemic encephalopathy secondary to hepatic arteriovenous malformations. She presented with disturbance of consciousness, and her serum ammonia level was elevated at 270 mg/dL. Color Doppler ultrasonography and contrast-enhanced computed tomography showed hepatic AVMs and shunts, which were useful for making the definite diagnosis. Portosystemic encephalopathy should be considered as a differential diagnosis in HHT patients presenting with disturbance of consciousness.
Collapse
Affiliation(s)
- Hiroyuki Kawabata
- Department of Gastroenterology, Saiseikai Matsusaka General Hospital, Japan
| | - Yasuhiko Hamada
- Department of Gastroenterology and Hepatology, Mie University Hospital, Japan
| | - Aiji Hattori
- Department of Gastroenterology, Saiseikai Matsusaka General Hospital, Japan
| | | |
Collapse
|
6
|
Hattori A, Kawabata H, Umeda Y, Tsuboi J, Yamada R, Hamada Y, Tanaka K. Adult hypertrophic pyloric stenosis that improved by spontaneous double channel pylorus formation. JGH Open 2021; 5:317-319. [PMID: 33553675 PMCID: PMC7857292 DOI: 10.1002/jgh3.12458] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/12/2020] [Revised: 10/10/2020] [Accepted: 11/08/2020] [Indexed: 11/16/2022]
Abstract
Adult hypertrophic pyloric stenosis (AHPS) is a rare disease and presents as pyloric obstruction. Double pylorus is also a rare condition due to a gastroduodenal fistula connecting from the gastric antrum to the duodenum. A 42‐year‐old woman without a history of vomiting in infancy presented with postprandial abdominal distension and repeated vomiting. Abdominal computed tomography showed gastric dilatation and wall thickening of the distal stomach. Endoscopy and contrast gastrography revealed gastric outlet obstruction due to stenosis and an ulcer in the antral and pyloric region. Endoscopic ultrasonography revealed circumferential thickening of the muscularis propria layer of the pylorus. Her symptoms improved with treatment consisting of drainage, fasting, and a proton pump inhibitor. Two weeks after onset, follow‐up endoscopy revealed a healing ulcer and double channel pylorus. Based on her clinical course and findings of clinical images, she was diagnosed with gastric outlet obstruction due to AHPS that was improved by double channel pylorus formation. In conclusion, AHPS that was improved by double channel pylorus formation is an extremely rare condition, and we should be aware of this disease entity.
Collapse
Affiliation(s)
- Aiji Hattori
- Department of Endoscopy Mie University Hospital Tsu Japan
- Department of Gastroenterology and Hepatology Mie University Hospital Tsu Japan
- Department of Gastroenterology Saiseikai Matsusaka General Hospital Matsusaka Japan
| | - Hiroyuki Kawabata
- Department of Gastroenterology Saiseikai Matsusaka General Hospital Matsusaka Japan
| | - Yuhei Umeda
- Department of Endoscopy Mie University Hospital Tsu Japan
- Department of Gastroenterology and Hepatology Mie University Hospital Tsu Japan
| | - Junya Tsuboi
- Department of Endoscopy Mie University Hospital Tsu Japan
- Department of Gastroenterology and Hepatology Mie University Hospital Tsu Japan
| | - Reiko Yamada
- Department of Gastroenterology and Hepatology Mie University Hospital Tsu Japan
| | - Yasuhiko Hamada
- Department of Gastroenterology and Hepatology Mie University Hospital Tsu Japan
| | - Kyosuke Tanaka
- Department of Endoscopy Mie University Hospital Tsu Japan
- Department of Gastroenterology and Hepatology Mie University Hospital Tsu Japan
| |
Collapse
|
7
|
Hattori A, Hamada Y, Kawabata H, Tanaka K. Acute liver injury secondary to hemophagocytic lymphohistiocytosis triggered by Epstein-Barr virus infection. JGH Open 2021; 5:166-168. [PMID: 33490632 PMCID: PMC7812516 DOI: 10.1002/jgh3.12439] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 07/01/2020] [Revised: 10/02/2020] [Accepted: 10/08/2020] [Indexed: 11/10/2022]
Abstract
We present a 23‐year‐old man with hemophagocytic lymphohistiocytosis (HLH) triggered by Epstein–Bar virus (EBV) infection. This patient presented with persistent fever and acute liver injury 6 weeks after having an infectious mononucleosis associated with EBV infection. He had hypofibrinogenemia, hyperferritinemia, increased soluble interleukin‐2 receptor, elevated prothrombin time, and pancytopenia. Bone marrow examination for evaluation of pancytopenia revealed that macrophages had phagocytosed mature erythrocytes. Based on these findings, we suspected an HLH triggered by EBV infection (EBV‐HLH). To distinguish from HLH triggered by malignant lymphomas accompanying EBV infection, we performed a percutaneous liver biopsy, which revealed that atypical T‐lymphocytes had infiltrated the liver tissues. The T‐lymphocytes were positive for EBV‐encoded RNA in situ hybridization, and no distinct monoclonal T‐cell receptor chain gene rearrangement was detected. These findings indicated EBV hepatitis and, accordingly, malignant lymphoma was ruled out. We finally made a diagnosis of EBV‐HLH. The patient was treated with corticosteroid and etoposide, according to HLH‐2004 guideline recommendations, and the patient's symptoms and laboratory values improved. After that, he experienced no recurrence. Prompt recognition and initiation of treatment remains the key to the survival of patients with EBV‐HLH, and the liver biopsy was helpful in making the diagnosis.
Collapse
Affiliation(s)
- Aiji Hattori
- Department of Gastroenterology Saiseikai Matsusaka General Hospital Matsusaka Japan
| | - Yasuhiko Hamada
- Department of Gastroenterology and Hepatology Mie University Hospital Tsu Japan
| | - Hiroyuki Kawabata
- Department of Gastroenterology Saiseikai Matsusaka General Hospital Matsusaka Japan
| | - Kyosuke Tanaka
- Department of Endoscopy Mie University Hospital Tsu Japan
| |
Collapse
|
8
|
Bando H, Masuda N, Yamanaka T, Kadoya T, Takahashi M, Nagai S, Ohtani S, Aruga T, Suzuki E, Kikawa Y, Yasojima H, Kasai H, Ishiguro H, Kawabata H, Morita S, Haga H, Kataoka T, Uozumi R, Ohno S, Toi M. 163MO Randomized phase II study of eribulin-based neoadjuvant chemotherapy for triple-negative primary breast cancer patients stratified by homologous recombination deficiency status (JBCRG-22). Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.285] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
9
|
Kawabata H, Yamashita S, Kikkawa K, Kohjimoto Y, Hara I. Screening of extended spectrum beta-lactamase is useful for preventing acute prostatitis after transrectal ultrasound guided prostate biopsy. EUR UROL SUPPL 2020. [DOI: 10.1016/s2666-1683(20)33594-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
10
|
Hattori A, Hamada Y, Kawabata H. An Unusual Gastric Lesion during Chemotherapy for Pancreatic Cancer. Gastroenterology 2020; 159:45-47. [PMID: 32205172 DOI: 10.1053/j.gastro.2020.02.064] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/21/2020] [Revised: 02/27/2020] [Accepted: 02/28/2020] [Indexed: 12/02/2022]
Affiliation(s)
- Aiji Hattori
- Department of Internal Medicine, Saiseikai Matsusaka General Hospital, Matsusaka, Japan
| | - Yasuhiko Hamada
- Department of Gastroenterology and Hepatology, Mie University Hospital, Tsu, Japan.
| | - Hiroyuki Kawabata
- Department of Internal Medicine, Saiseikai Matsusaka General Hospital, Matsusaka, Japan
| |
Collapse
|
11
|
Ozaki Y, Takahashi M, Tanabe Y, Miura Y, Tamura N, Shigekawa T, Kawabata H, Baba N, Iguchi H, Takano T. Atypical femoral fracture in breast cancer patients with bone metastasis receiving denosumab therapy: multi-center retrospective analysis. Breast 2019. [DOI: 10.1016/s0960-9776(19)30450-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022] Open
|
12
|
Kawabata H, Azuma K, Ikeda K, Sugitani I, Kinowaki K, Fujii T, Osaki A, Saeki T, Horie-Inoue K, Inoue S. Abstract P3-07-06: TRIM44 is a possible poor prognostic factor for breast cancer patients and positively regulates NF-κB signaling pathway. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-p3-07-06] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
[Background]
Many of the tripartite motif (TRIM) proteins, like Efp/TRIM25 which was identified by our group previously (Nature 417, 871-875, 2002), function as E3 ubiquitin ligases, and are thought to be involved in various physiological and pathological processes such as immunity and oncogenesis. In regard to tripartite motif containing 44 (TRIM44), which is an atypical TRIM family protein lacking RING finger domain, some evidences suggest that it is implicated in the progression of several human malignancies. But its pathophysiological significance in breast cancer remains unknown.
[Methods]
In the present study, immunohistochemical analysis using anti-TRIM44 antibody was performed in clinical breast cancer tissues from 129 patients with the approval of institutional ethical committees (approval number: 845). We then explored the pathophysiological role of TRIM44 in breast cancer by modulating TRIM44 expression in MCF-7 and MDA-MB-231 breast cancer cells.
[Results]
TRIM44 strong immunoreactivity was significantly associated with nuclear grade, distant disease-free survival and overall survival of the breast cancer patients. With multivariate analysis it was shown that the TRIM44 status was an independent prognostic factor for distant disease-free survival and overall survival. The proliferation of MCF-7 and MDA-MB-231 cells was significantly decreased by siRNA-mediated TRIM44 knockdown. TRIM44 knockdown also suppressed migration of MDA-MB-231 cells. Microarray analysis and qRT-PCR revealed that TRIM44 knockdown upregulated CDK19 (Cyclin Dependent Kinase 19), which is reported to be a tumor suppressor gene, whereas downregulated MMP1 (Matrix Metallopeptidase 1) in MDA-MB-231 cells. Notably, TRIM44 knockdown impaired nuclear factor-kappa B (NF-κB)-mediated transcriptional activity stimulated by tumor necrosis factor α (TNFα). Moreover, TRIM44 knockdown substantially attenuated the TNFα-dependent phosphorylation of p65 subunit of NF-κB and IκBα in both MCF-7 and MDA-MB-231 cells.
[Discussion]
Our clinical study showed that prognosis of breast cancer patients is correlated with the immunoreactivity detected by anti-TRIM44 antibody. This result suggested that expression of TRIM44 protein could be used as a potential biomarker of breast cancer. We demonstrated that NF-κB signaling pathway is modulated by TRIM44. Since NF-κB augmentation is shown to be related to aggressive character of breast cancer, stimulation of NF-κB signaling with TRIM44 might be underlying mechanism of poor prognosis. Our in vitro study showed TRIM44 knockdown caused attenuated proliferation and migration of breast cancer cells, raising the possibility of TRIM44 as a potential therapeutic target for breast cancer. These findings provide new clues to develop alternative effective strategies for breast cancer management.
Citation Format: Kawabata H, Azuma K, Ikeda K, Sugitani I, Kinowaki K, Fujii T, Osaki A, Saeki T, Horie-Inoue K, Inoue S. TRIM44 is a possible poor prognostic factor for breast cancer patients and positively regulates NF-κB signaling pathway [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P3-07-06.
Collapse
Affiliation(s)
- H Kawabata
- Tokyo Metropolitan Institue of Gerontology, Tokyo, Itabashi-ku, Japan; Research Center for Genomic Medicine, Saitama Medical University, Hidaka, Saitama, Japan; Saitama Medical University International Medical Center, Hidaka, Saitama, Japan; Toranomon Hospital, Minato-ku, Tokyo, Japan
| | - K Azuma
- Tokyo Metropolitan Institue of Gerontology, Tokyo, Itabashi-ku, Japan; Research Center for Genomic Medicine, Saitama Medical University, Hidaka, Saitama, Japan; Saitama Medical University International Medical Center, Hidaka, Saitama, Japan; Toranomon Hospital, Minato-ku, Tokyo, Japan
| | - K Ikeda
- Tokyo Metropolitan Institue of Gerontology, Tokyo, Itabashi-ku, Japan; Research Center for Genomic Medicine, Saitama Medical University, Hidaka, Saitama, Japan; Saitama Medical University International Medical Center, Hidaka, Saitama, Japan; Toranomon Hospital, Minato-ku, Tokyo, Japan
| | - I Sugitani
- Tokyo Metropolitan Institue of Gerontology, Tokyo, Itabashi-ku, Japan; Research Center for Genomic Medicine, Saitama Medical University, Hidaka, Saitama, Japan; Saitama Medical University International Medical Center, Hidaka, Saitama, Japan; Toranomon Hospital, Minato-ku, Tokyo, Japan
| | - K Kinowaki
- Tokyo Metropolitan Institue of Gerontology, Tokyo, Itabashi-ku, Japan; Research Center for Genomic Medicine, Saitama Medical University, Hidaka, Saitama, Japan; Saitama Medical University International Medical Center, Hidaka, Saitama, Japan; Toranomon Hospital, Minato-ku, Tokyo, Japan
| | - T Fujii
- Tokyo Metropolitan Institue of Gerontology, Tokyo, Itabashi-ku, Japan; Research Center for Genomic Medicine, Saitama Medical University, Hidaka, Saitama, Japan; Saitama Medical University International Medical Center, Hidaka, Saitama, Japan; Toranomon Hospital, Minato-ku, Tokyo, Japan
| | - A Osaki
- Tokyo Metropolitan Institue of Gerontology, Tokyo, Itabashi-ku, Japan; Research Center for Genomic Medicine, Saitama Medical University, Hidaka, Saitama, Japan; Saitama Medical University International Medical Center, Hidaka, Saitama, Japan; Toranomon Hospital, Minato-ku, Tokyo, Japan
| | - T Saeki
- Tokyo Metropolitan Institue of Gerontology, Tokyo, Itabashi-ku, Japan; Research Center for Genomic Medicine, Saitama Medical University, Hidaka, Saitama, Japan; Saitama Medical University International Medical Center, Hidaka, Saitama, Japan; Toranomon Hospital, Minato-ku, Tokyo, Japan
| | - K Horie-Inoue
- Tokyo Metropolitan Institue of Gerontology, Tokyo, Itabashi-ku, Japan; Research Center for Genomic Medicine, Saitama Medical University, Hidaka, Saitama, Japan; Saitama Medical University International Medical Center, Hidaka, Saitama, Japan; Toranomon Hospital, Minato-ku, Tokyo, Japan
| | - S Inoue
- Tokyo Metropolitan Institue of Gerontology, Tokyo, Itabashi-ku, Japan; Research Center for Genomic Medicine, Saitama Medical University, Hidaka, Saitama, Japan; Saitama Medical University International Medical Center, Hidaka, Saitama, Japan; Toranomon Hospital, Minato-ku, Tokyo, Japan
| |
Collapse
|
13
|
Takano T, Tsurutani J, Takahashi M, Yamanaka T, Sakai K, Ito Y, Fukuoka J, Kimura H, Kawabata H, Tamura K, Matsumoto K, Aogi K, Sato K, Nishio K, Nakagawa K, Saeki T. Abstract P4-21-14: A randomized phase II trial of trastuzumab + capecitabine versus lapatinib + capecitabine in patients with HER2-positive metastatic breast cancer previously treated with trastuzumab and taxanes: WJOG6110B/ELTOP. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p4-21-14] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: In patients with HER2-positive metastatic breast cancer (MBC) who progressed on trastuzumab (H)-based therapy, both continuing H beyond progression and switching to lapatinib (L) in combination with chemotherapy are valid options. However, it is unclear which strategy is more effective and how we can select a proper strategy in each patient.
Methods: We conducted an open label, multicenter, randomized phase II trial to comparatively evaluate efficacy and safety of H + capecitabine (X) (HX) or L + X (LX) in women with HER2-positive MBC who were previously treated with taxanes and progressed on H-containing regimens. Patients treated with more than two chemotherapy regimens for MBC were excluded. Those treated with pertuzumab and/or T-DM1 were allowed to enroll in this study. Patients with brain metastases were also included if they are asymptomatic. Patients received H (4mg/kg loading then 2mg/kg weekly or 8mg/kg loading then 6mg/kg every 3 weeks) and X (2500 mg/m2/day on days 1-14 every 3weeks) in HX arm and L (1250 mg/day) and X (2000 mg/m2/day on days 1-14 every 3weeks) in LX arm until progression or intolerable toxicity. The primary endpoint was progression-free survival (PFS) and secondary endpoints included overall survival (OS), objective response rate (ORR), proportion of subjects progressing with brain metastases as site of first progression, and safety.We also assessed biomarkers in tumor tissues and circulating cell-free DNA.
Results: Between May 2011 and December 2014, 86 patients (43 in HX arm and 43 in LX arm) were enrolled in this study. Median age was 58 years (range 34-81), ECOG performance status was 0 (63%), 1 (35%), or 2 (2%), 63% had hormone receptor-positive disease, 15% had brain metastases, 56% had relapsed after primary surgery, and 23% had received adjuvant or neo-adjuvant trastuzumab. Median follow-up time was 44.6 months. Median PFS was 6.1 months in HX arm and 7.1 months in LX arm (hazard ratio 0.81 90% CI 0.55-1.21; p=0.39), median OS was 31.0 months in HX arm and not reached in LX arm (hazard ratio 0.58 95% CI 0.26-1.31; p=0.18), ORR was 40% in HX arm and 41% in LX arm (p=1.00), disease control rate was 73% in HX arm and 92% in LX arm (p=0.038), and proportion of subjects progressing with brain metastases as site of first progression was 5% in HX arm and 5% in LX arm. Grade 3-4 toxicities included hand-foot syndrome (21% in HX arm and 21% in LX arm) and diarrhea (9% in HX arm and 16% in LX arm). In subgroup analyses, PFS benefit in LX arm compared to HX arm was significantly larger among patients who had received previous systemic treatment for metastatic disease for less than 1 year (interaction p=0.007). Subgroup analyses by biomarkers will be presented at the meeting.
Conclusions: In women with HER2-positive MBC previously treated with trastuzumab and taxanes, lapatinib + capecitabine tended to yield better PFS and OS than trastuzumab beyond progression + capecitabine, although they were not statistically significant.Background: In patients with HER2-positive metastatic breast cancer (MBC) who progressed on trastuzumab (H)-based therapy, both continuing H beyond progression and switching to lapatinib (L) in combination with chemotherapy are valid options. However, it is unclear which strategy is more effective and how we can select a proper strategy in each patient.
Methods: We conducted an open label, multicenter, randomized phase II trial to comparatively evaluate efficacy and safety of H + capecitabine (X) (HX) or L + X (LX) in women with HER2-positive MBC who were previously treated with taxanes and progressed on H-containing regimens. Patients treated with more than two chemotherapy regimens for MBC were excluded. Those treated with pertuzumab and/or T-DM1 were allowed to enroll in this study. Patients with brain metastases were also included if they are asymptomatic. Patients received H (4mg/kg loading then 2mg/kg weekly or 8mg/kg loading then 6mg/kg every 3 weeks) and X (2500 mg/m2/day on days 1-14 every 3weeks) in HX arm and L (1250 mg/day) and X (2000 mg/m2/day on days 1-14 every 3weeks) in LX arm until progression or intolerable toxicity. The primary endpoint was progression-free survival (PFS) and secondary endpoints included overall survival (OS), objective response rate (ORR), proportion of subjects progressing with brain metastases as site of first progression, and safety.We also assessed biomarkers in tumor tissues and circulating cell-free DNA.
Results: Between May 2011 and December 2014, 86 patients (43 in HX arm and 43 in LX arm) were enrolled in this study. Median age was 58 years (range 34-81), ECOG performance status was 0 (63%), 1 (35%), or 2 (2%), 63% had hormone receptor-positive disease, 15% had brain metastases, 56% had relapsed after primary surgery, and 23% had received adjuvant or neo-adjuvant trastuzumab. Median follow-up time was 44.6 months. Median PFS was 6.1 months in HX arm and 7.1 months in LX arm (hazard ratio 0.81 90% CI 0.55-1.21; p=0.39), median OS was 31.0 months in HX arm and not reached in LX arm (hazard ratio 0.58 95% CI 0.26-1.31; p=0.18), ORR was 40% in HX arm and 41% in LX arm (p=1.00), disease control rate was 73% in HX arm and 92% in LX arm (p=0.038), and proportion of subjects progressing with brain metastases as site of first progression was 5% in HX arm and 5% in LX arm. Grade 3-4 toxicities included hand-foot syndrome (21% in HX arm and 21% in LX arm) and diarrhea (9% in HX arm and 16% in LX arm). In subgroup analyses, PFS benefit in LX arm compared to HX arm was significantly larger among patients who had received previous systemic treatment for metastatic disease for less than 1 year (interaction p=0.007). Subgroup analyses by biomarkers will be presented at the meeting.
Conclusions: In women with HER2-positive MBC previously treated with trastuzumab and taxanes, lapatinib + capecitabine tended to yield better PFS and OS than trastuzumab beyond progression + capecitabine, although they were not statistically significant.
Citation Format: Takano T, Tsurutani J, Takahashi M, Yamanaka T, Sakai K, Ito Y, Fukuoka J, Kimura H, Kawabata H, Tamura K, Matsumoto K, Aogi K, Sato K, Nishio K, Nakagawa K, Saeki T. A randomized phase II trial of trastuzumab + capecitabine versus lapatinib + capecitabine in patients with HER2-positive metastatic breast cancer previously treated with trastuzumab and taxanes: WJOG6110B/ELTOP [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P4-21-14.
Collapse
Affiliation(s)
- T Takano
- Toranomon Hospital, Tokyo, Japan; Kindai University, Osaka, Japan; NHO Hokkaido Cancer Center, Hokkaido, Japan; Yokohama City University, Kanagawa, Japan; Cancer Institute Hospital, Tokyo, Japan; Pathology Institute, Toyama, Japan; Kanazawa University, Ishikawa, Japan; National Cancer Center Hospital, Tokyo, Japan; Hyogo Cancer Center, Hyogo, Japan; Shikoku Cancer Center, Ehime, Japan; Tokyo-West Tokushukai Hospital, Tokyo, Japan; Saitama Medical University, Saitama, Japan
| | - J Tsurutani
- Toranomon Hospital, Tokyo, Japan; Kindai University, Osaka, Japan; NHO Hokkaido Cancer Center, Hokkaido, Japan; Yokohama City University, Kanagawa, Japan; Cancer Institute Hospital, Tokyo, Japan; Pathology Institute, Toyama, Japan; Kanazawa University, Ishikawa, Japan; National Cancer Center Hospital, Tokyo, Japan; Hyogo Cancer Center, Hyogo, Japan; Shikoku Cancer Center, Ehime, Japan; Tokyo-West Tokushukai Hospital, Tokyo, Japan; Saitama Medical University, Saitama, Japan
| | - M Takahashi
- Toranomon Hospital, Tokyo, Japan; Kindai University, Osaka, Japan; NHO Hokkaido Cancer Center, Hokkaido, Japan; Yokohama City University, Kanagawa, Japan; Cancer Institute Hospital, Tokyo, Japan; Pathology Institute, Toyama, Japan; Kanazawa University, Ishikawa, Japan; National Cancer Center Hospital, Tokyo, Japan; Hyogo Cancer Center, Hyogo, Japan; Shikoku Cancer Center, Ehime, Japan; Tokyo-West Tokushukai Hospital, Tokyo, Japan; Saitama Medical University, Saitama, Japan
| | - T Yamanaka
- Toranomon Hospital, Tokyo, Japan; Kindai University, Osaka, Japan; NHO Hokkaido Cancer Center, Hokkaido, Japan; Yokohama City University, Kanagawa, Japan; Cancer Institute Hospital, Tokyo, Japan; Pathology Institute, Toyama, Japan; Kanazawa University, Ishikawa, Japan; National Cancer Center Hospital, Tokyo, Japan; Hyogo Cancer Center, Hyogo, Japan; Shikoku Cancer Center, Ehime, Japan; Tokyo-West Tokushukai Hospital, Tokyo, Japan; Saitama Medical University, Saitama, Japan
| | - K Sakai
- Toranomon Hospital, Tokyo, Japan; Kindai University, Osaka, Japan; NHO Hokkaido Cancer Center, Hokkaido, Japan; Yokohama City University, Kanagawa, Japan; Cancer Institute Hospital, Tokyo, Japan; Pathology Institute, Toyama, Japan; Kanazawa University, Ishikawa, Japan; National Cancer Center Hospital, Tokyo, Japan; Hyogo Cancer Center, Hyogo, Japan; Shikoku Cancer Center, Ehime, Japan; Tokyo-West Tokushukai Hospital, Tokyo, Japan; Saitama Medical University, Saitama, Japan
| | - Y Ito
- Toranomon Hospital, Tokyo, Japan; Kindai University, Osaka, Japan; NHO Hokkaido Cancer Center, Hokkaido, Japan; Yokohama City University, Kanagawa, Japan; Cancer Institute Hospital, Tokyo, Japan; Pathology Institute, Toyama, Japan; Kanazawa University, Ishikawa, Japan; National Cancer Center Hospital, Tokyo, Japan; Hyogo Cancer Center, Hyogo, Japan; Shikoku Cancer Center, Ehime, Japan; Tokyo-West Tokushukai Hospital, Tokyo, Japan; Saitama Medical University, Saitama, Japan
| | - J Fukuoka
- Toranomon Hospital, Tokyo, Japan; Kindai University, Osaka, Japan; NHO Hokkaido Cancer Center, Hokkaido, Japan; Yokohama City University, Kanagawa, Japan; Cancer Institute Hospital, Tokyo, Japan; Pathology Institute, Toyama, Japan; Kanazawa University, Ishikawa, Japan; National Cancer Center Hospital, Tokyo, Japan; Hyogo Cancer Center, Hyogo, Japan; Shikoku Cancer Center, Ehime, Japan; Tokyo-West Tokushukai Hospital, Tokyo, Japan; Saitama Medical University, Saitama, Japan
| | - H Kimura
- Toranomon Hospital, Tokyo, Japan; Kindai University, Osaka, Japan; NHO Hokkaido Cancer Center, Hokkaido, Japan; Yokohama City University, Kanagawa, Japan; Cancer Institute Hospital, Tokyo, Japan; Pathology Institute, Toyama, Japan; Kanazawa University, Ishikawa, Japan; National Cancer Center Hospital, Tokyo, Japan; Hyogo Cancer Center, Hyogo, Japan; Shikoku Cancer Center, Ehime, Japan; Tokyo-West Tokushukai Hospital, Tokyo, Japan; Saitama Medical University, Saitama, Japan
| | - H Kawabata
- Toranomon Hospital, Tokyo, Japan; Kindai University, Osaka, Japan; NHO Hokkaido Cancer Center, Hokkaido, Japan; Yokohama City University, Kanagawa, Japan; Cancer Institute Hospital, Tokyo, Japan; Pathology Institute, Toyama, Japan; Kanazawa University, Ishikawa, Japan; National Cancer Center Hospital, Tokyo, Japan; Hyogo Cancer Center, Hyogo, Japan; Shikoku Cancer Center, Ehime, Japan; Tokyo-West Tokushukai Hospital, Tokyo, Japan; Saitama Medical University, Saitama, Japan
| | - K Tamura
- Toranomon Hospital, Tokyo, Japan; Kindai University, Osaka, Japan; NHO Hokkaido Cancer Center, Hokkaido, Japan; Yokohama City University, Kanagawa, Japan; Cancer Institute Hospital, Tokyo, Japan; Pathology Institute, Toyama, Japan; Kanazawa University, Ishikawa, Japan; National Cancer Center Hospital, Tokyo, Japan; Hyogo Cancer Center, Hyogo, Japan; Shikoku Cancer Center, Ehime, Japan; Tokyo-West Tokushukai Hospital, Tokyo, Japan; Saitama Medical University, Saitama, Japan
| | - K Matsumoto
- Toranomon Hospital, Tokyo, Japan; Kindai University, Osaka, Japan; NHO Hokkaido Cancer Center, Hokkaido, Japan; Yokohama City University, Kanagawa, Japan; Cancer Institute Hospital, Tokyo, Japan; Pathology Institute, Toyama, Japan; Kanazawa University, Ishikawa, Japan; National Cancer Center Hospital, Tokyo, Japan; Hyogo Cancer Center, Hyogo, Japan; Shikoku Cancer Center, Ehime, Japan; Tokyo-West Tokushukai Hospital, Tokyo, Japan; Saitama Medical University, Saitama, Japan
| | - K Aogi
- Toranomon Hospital, Tokyo, Japan; Kindai University, Osaka, Japan; NHO Hokkaido Cancer Center, Hokkaido, Japan; Yokohama City University, Kanagawa, Japan; Cancer Institute Hospital, Tokyo, Japan; Pathology Institute, Toyama, Japan; Kanazawa University, Ishikawa, Japan; National Cancer Center Hospital, Tokyo, Japan; Hyogo Cancer Center, Hyogo, Japan; Shikoku Cancer Center, Ehime, Japan; Tokyo-West Tokushukai Hospital, Tokyo, Japan; Saitama Medical University, Saitama, Japan
| | - K Sato
- Toranomon Hospital, Tokyo, Japan; Kindai University, Osaka, Japan; NHO Hokkaido Cancer Center, Hokkaido, Japan; Yokohama City University, Kanagawa, Japan; Cancer Institute Hospital, Tokyo, Japan; Pathology Institute, Toyama, Japan; Kanazawa University, Ishikawa, Japan; National Cancer Center Hospital, Tokyo, Japan; Hyogo Cancer Center, Hyogo, Japan; Shikoku Cancer Center, Ehime, Japan; Tokyo-West Tokushukai Hospital, Tokyo, Japan; Saitama Medical University, Saitama, Japan
| | - K Nishio
- Toranomon Hospital, Tokyo, Japan; Kindai University, Osaka, Japan; NHO Hokkaido Cancer Center, Hokkaido, Japan; Yokohama City University, Kanagawa, Japan; Cancer Institute Hospital, Tokyo, Japan; Pathology Institute, Toyama, Japan; Kanazawa University, Ishikawa, Japan; National Cancer Center Hospital, Tokyo, Japan; Hyogo Cancer Center, Hyogo, Japan; Shikoku Cancer Center, Ehime, Japan; Tokyo-West Tokushukai Hospital, Tokyo, Japan; Saitama Medical University, Saitama, Japan
| | - K Nakagawa
- Toranomon Hospital, Tokyo, Japan; Kindai University, Osaka, Japan; NHO Hokkaido Cancer Center, Hokkaido, Japan; Yokohama City University, Kanagawa, Japan; Cancer Institute Hospital, Tokyo, Japan; Pathology Institute, Toyama, Japan; Kanazawa University, Ishikawa, Japan; National Cancer Center Hospital, Tokyo, Japan; Hyogo Cancer Center, Hyogo, Japan; Shikoku Cancer Center, Ehime, Japan; Tokyo-West Tokushukai Hospital, Tokyo, Japan; Saitama Medical University, Saitama, Japan
| | - T Saeki
- Toranomon Hospital, Tokyo, Japan; Kindai University, Osaka, Japan; NHO Hokkaido Cancer Center, Hokkaido, Japan; Yokohama City University, Kanagawa, Japan; Cancer Institute Hospital, Tokyo, Japan; Pathology Institute, Toyama, Japan; Kanazawa University, Ishikawa, Japan; National Cancer Center Hospital, Tokyo, Japan; Hyogo Cancer Center, Hyogo, Japan; Shikoku Cancer Center, Ehime, Japan; Tokyo-West Tokushukai Hospital, Tokyo, Japan; Saitama Medical University, Saitama, Japan
| |
Collapse
|
14
|
Tsurutani J, Sakai K, Takao T, Kimura H, Kawabata H, Tanaka K, Takahashi M, Ito Y, Takao S, Aogi K, Sato K, Tsuji Y, Yamanaka T, Nakanishi Y, Saeki T, Nishio K. Abstract P2-05-24: Prognostic value of circulating PIK3CA mutations revealed with digital PCR in patients with HER2-positive advanced breast cancer: Results of West Japan Oncology Group study 6110BTR. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p2-05-24] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
This abstract was withdrawn by the authors.
Collapse
Affiliation(s)
- J Tsurutani
- Kindai University Faculty of Medicine, Osakasayama, Osaka, Japan; Toranomon Hospital, Minato, Tokyo, Japan; Respiratory Medicine, Kanazawa University Hospital, Kanazawa, Ishikawa, Japan; NHO Hokkaido Cancer Center, Sapporo, Hokaido, Japan; Cancer Institute Hospital, Japanese Foundation for Cancer Research, Kotoh, Tokyo, Japan; Hyogo Cancer Center, Akashi, Hyogo, Japan; National Shikoku Cancer Center Hospital, Matsuyama, Ehime, Japan; Tokyo-West Tokushukai Hospital, Akishima, Tokyo, Japan; Tonan Hospital, Sapporo, Hokkaido, Japan; Yokohama City University, Yokohama, Kanagawa, Japan; Kyushu University, Fukuoka, Japan; Saitama Medical University International Medical Center, Hidaka, Saitama, Japan
| | - K Sakai
- Kindai University Faculty of Medicine, Osakasayama, Osaka, Japan; Toranomon Hospital, Minato, Tokyo, Japan; Respiratory Medicine, Kanazawa University Hospital, Kanazawa, Ishikawa, Japan; NHO Hokkaido Cancer Center, Sapporo, Hokaido, Japan; Cancer Institute Hospital, Japanese Foundation for Cancer Research, Kotoh, Tokyo, Japan; Hyogo Cancer Center, Akashi, Hyogo, Japan; National Shikoku Cancer Center Hospital, Matsuyama, Ehime, Japan; Tokyo-West Tokushukai Hospital, Akishima, Tokyo, Japan; Tonan Hospital, Sapporo, Hokkaido, Japan; Yokohama City University, Yokohama, Kanagawa, Japan; Kyushu University, Fukuoka, Japan; Saitama Medical University International Medical Center, Hidaka, Saitama, Japan
| | - T Takao
- Kindai University Faculty of Medicine, Osakasayama, Osaka, Japan; Toranomon Hospital, Minato, Tokyo, Japan; Respiratory Medicine, Kanazawa University Hospital, Kanazawa, Ishikawa, Japan; NHO Hokkaido Cancer Center, Sapporo, Hokaido, Japan; Cancer Institute Hospital, Japanese Foundation for Cancer Research, Kotoh, Tokyo, Japan; Hyogo Cancer Center, Akashi, Hyogo, Japan; National Shikoku Cancer Center Hospital, Matsuyama, Ehime, Japan; Tokyo-West Tokushukai Hospital, Akishima, Tokyo, Japan; Tonan Hospital, Sapporo, Hokkaido, Japan; Yokohama City University, Yokohama, Kanagawa, Japan; Kyushu University, Fukuoka, Japan; Saitama Medical University International Medical Center, Hidaka, Saitama, Japan
| | - H Kimura
- Kindai University Faculty of Medicine, Osakasayama, Osaka, Japan; Toranomon Hospital, Minato, Tokyo, Japan; Respiratory Medicine, Kanazawa University Hospital, Kanazawa, Ishikawa, Japan; NHO Hokkaido Cancer Center, Sapporo, Hokaido, Japan; Cancer Institute Hospital, Japanese Foundation for Cancer Research, Kotoh, Tokyo, Japan; Hyogo Cancer Center, Akashi, Hyogo, Japan; National Shikoku Cancer Center Hospital, Matsuyama, Ehime, Japan; Tokyo-West Tokushukai Hospital, Akishima, Tokyo, Japan; Tonan Hospital, Sapporo, Hokkaido, Japan; Yokohama City University, Yokohama, Kanagawa, Japan; Kyushu University, Fukuoka, Japan; Saitama Medical University International Medical Center, Hidaka, Saitama, Japan
| | - H Kawabata
- Kindai University Faculty of Medicine, Osakasayama, Osaka, Japan; Toranomon Hospital, Minato, Tokyo, Japan; Respiratory Medicine, Kanazawa University Hospital, Kanazawa, Ishikawa, Japan; NHO Hokkaido Cancer Center, Sapporo, Hokaido, Japan; Cancer Institute Hospital, Japanese Foundation for Cancer Research, Kotoh, Tokyo, Japan; Hyogo Cancer Center, Akashi, Hyogo, Japan; National Shikoku Cancer Center Hospital, Matsuyama, Ehime, Japan; Tokyo-West Tokushukai Hospital, Akishima, Tokyo, Japan; Tonan Hospital, Sapporo, Hokkaido, Japan; Yokohama City University, Yokohama, Kanagawa, Japan; Kyushu University, Fukuoka, Japan; Saitama Medical University International Medical Center, Hidaka, Saitama, Japan
| | - K Tanaka
- Kindai University Faculty of Medicine, Osakasayama, Osaka, Japan; Toranomon Hospital, Minato, Tokyo, Japan; Respiratory Medicine, Kanazawa University Hospital, Kanazawa, Ishikawa, Japan; NHO Hokkaido Cancer Center, Sapporo, Hokaido, Japan; Cancer Institute Hospital, Japanese Foundation for Cancer Research, Kotoh, Tokyo, Japan; Hyogo Cancer Center, Akashi, Hyogo, Japan; National Shikoku Cancer Center Hospital, Matsuyama, Ehime, Japan; Tokyo-West Tokushukai Hospital, Akishima, Tokyo, Japan; Tonan Hospital, Sapporo, Hokkaido, Japan; Yokohama City University, Yokohama, Kanagawa, Japan; Kyushu University, Fukuoka, Japan; Saitama Medical University International Medical Center, Hidaka, Saitama, Japan
| | - M Takahashi
- Kindai University Faculty of Medicine, Osakasayama, Osaka, Japan; Toranomon Hospital, Minato, Tokyo, Japan; Respiratory Medicine, Kanazawa University Hospital, Kanazawa, Ishikawa, Japan; NHO Hokkaido Cancer Center, Sapporo, Hokaido, Japan; Cancer Institute Hospital, Japanese Foundation for Cancer Research, Kotoh, Tokyo, Japan; Hyogo Cancer Center, Akashi, Hyogo, Japan; National Shikoku Cancer Center Hospital, Matsuyama, Ehime, Japan; Tokyo-West Tokushukai Hospital, Akishima, Tokyo, Japan; Tonan Hospital, Sapporo, Hokkaido, Japan; Yokohama City University, Yokohama, Kanagawa, Japan; Kyushu University, Fukuoka, Japan; Saitama Medical University International Medical Center, Hidaka, Saitama, Japan
| | - Y Ito
- Kindai University Faculty of Medicine, Osakasayama, Osaka, Japan; Toranomon Hospital, Minato, Tokyo, Japan; Respiratory Medicine, Kanazawa University Hospital, Kanazawa, Ishikawa, Japan; NHO Hokkaido Cancer Center, Sapporo, Hokaido, Japan; Cancer Institute Hospital, Japanese Foundation for Cancer Research, Kotoh, Tokyo, Japan; Hyogo Cancer Center, Akashi, Hyogo, Japan; National Shikoku Cancer Center Hospital, Matsuyama, Ehime, Japan; Tokyo-West Tokushukai Hospital, Akishima, Tokyo, Japan; Tonan Hospital, Sapporo, Hokkaido, Japan; Yokohama City University, Yokohama, Kanagawa, Japan; Kyushu University, Fukuoka, Japan; Saitama Medical University International Medical Center, Hidaka, Saitama, Japan
| | - S Takao
- Kindai University Faculty of Medicine, Osakasayama, Osaka, Japan; Toranomon Hospital, Minato, Tokyo, Japan; Respiratory Medicine, Kanazawa University Hospital, Kanazawa, Ishikawa, Japan; NHO Hokkaido Cancer Center, Sapporo, Hokaido, Japan; Cancer Institute Hospital, Japanese Foundation for Cancer Research, Kotoh, Tokyo, Japan; Hyogo Cancer Center, Akashi, Hyogo, Japan; National Shikoku Cancer Center Hospital, Matsuyama, Ehime, Japan; Tokyo-West Tokushukai Hospital, Akishima, Tokyo, Japan; Tonan Hospital, Sapporo, Hokkaido, Japan; Yokohama City University, Yokohama, Kanagawa, Japan; Kyushu University, Fukuoka, Japan; Saitama Medical University International Medical Center, Hidaka, Saitama, Japan
| | - K Aogi
- Kindai University Faculty of Medicine, Osakasayama, Osaka, Japan; Toranomon Hospital, Minato, Tokyo, Japan; Respiratory Medicine, Kanazawa University Hospital, Kanazawa, Ishikawa, Japan; NHO Hokkaido Cancer Center, Sapporo, Hokaido, Japan; Cancer Institute Hospital, Japanese Foundation for Cancer Research, Kotoh, Tokyo, Japan; Hyogo Cancer Center, Akashi, Hyogo, Japan; National Shikoku Cancer Center Hospital, Matsuyama, Ehime, Japan; Tokyo-West Tokushukai Hospital, Akishima, Tokyo, Japan; Tonan Hospital, Sapporo, Hokkaido, Japan; Yokohama City University, Yokohama, Kanagawa, Japan; Kyushu University, Fukuoka, Japan; Saitama Medical University International Medical Center, Hidaka, Saitama, Japan
| | - K Sato
- Kindai University Faculty of Medicine, Osakasayama, Osaka, Japan; Toranomon Hospital, Minato, Tokyo, Japan; Respiratory Medicine, Kanazawa University Hospital, Kanazawa, Ishikawa, Japan; NHO Hokkaido Cancer Center, Sapporo, Hokaido, Japan; Cancer Institute Hospital, Japanese Foundation for Cancer Research, Kotoh, Tokyo, Japan; Hyogo Cancer Center, Akashi, Hyogo, Japan; National Shikoku Cancer Center Hospital, Matsuyama, Ehime, Japan; Tokyo-West Tokushukai Hospital, Akishima, Tokyo, Japan; Tonan Hospital, Sapporo, Hokkaido, Japan; Yokohama City University, Yokohama, Kanagawa, Japan; Kyushu University, Fukuoka, Japan; Saitama Medical University International Medical Center, Hidaka, Saitama, Japan
| | - Y Tsuji
- Kindai University Faculty of Medicine, Osakasayama, Osaka, Japan; Toranomon Hospital, Minato, Tokyo, Japan; Respiratory Medicine, Kanazawa University Hospital, Kanazawa, Ishikawa, Japan; NHO Hokkaido Cancer Center, Sapporo, Hokaido, Japan; Cancer Institute Hospital, Japanese Foundation for Cancer Research, Kotoh, Tokyo, Japan; Hyogo Cancer Center, Akashi, Hyogo, Japan; National Shikoku Cancer Center Hospital, Matsuyama, Ehime, Japan; Tokyo-West Tokushukai Hospital, Akishima, Tokyo, Japan; Tonan Hospital, Sapporo, Hokkaido, Japan; Yokohama City University, Yokohama, Kanagawa, Japan; Kyushu University, Fukuoka, Japan; Saitama Medical University International Medical Center, Hidaka, Saitama, Japan
| | - T Yamanaka
- Kindai University Faculty of Medicine, Osakasayama, Osaka, Japan; Toranomon Hospital, Minato, Tokyo, Japan; Respiratory Medicine, Kanazawa University Hospital, Kanazawa, Ishikawa, Japan; NHO Hokkaido Cancer Center, Sapporo, Hokaido, Japan; Cancer Institute Hospital, Japanese Foundation for Cancer Research, Kotoh, Tokyo, Japan; Hyogo Cancer Center, Akashi, Hyogo, Japan; National Shikoku Cancer Center Hospital, Matsuyama, Ehime, Japan; Tokyo-West Tokushukai Hospital, Akishima, Tokyo, Japan; Tonan Hospital, Sapporo, Hokkaido, Japan; Yokohama City University, Yokohama, Kanagawa, Japan; Kyushu University, Fukuoka, Japan; Saitama Medical University International Medical Center, Hidaka, Saitama, Japan
| | - Y Nakanishi
- Kindai University Faculty of Medicine, Osakasayama, Osaka, Japan; Toranomon Hospital, Minato, Tokyo, Japan; Respiratory Medicine, Kanazawa University Hospital, Kanazawa, Ishikawa, Japan; NHO Hokkaido Cancer Center, Sapporo, Hokaido, Japan; Cancer Institute Hospital, Japanese Foundation for Cancer Research, Kotoh, Tokyo, Japan; Hyogo Cancer Center, Akashi, Hyogo, Japan; National Shikoku Cancer Center Hospital, Matsuyama, Ehime, Japan; Tokyo-West Tokushukai Hospital, Akishima, Tokyo, Japan; Tonan Hospital, Sapporo, Hokkaido, Japan; Yokohama City University, Yokohama, Kanagawa, Japan; Kyushu University, Fukuoka, Japan; Saitama Medical University International Medical Center, Hidaka, Saitama, Japan
| | - T Saeki
- Kindai University Faculty of Medicine, Osakasayama, Osaka, Japan; Toranomon Hospital, Minato, Tokyo, Japan; Respiratory Medicine, Kanazawa University Hospital, Kanazawa, Ishikawa, Japan; NHO Hokkaido Cancer Center, Sapporo, Hokaido, Japan; Cancer Institute Hospital, Japanese Foundation for Cancer Research, Kotoh, Tokyo, Japan; Hyogo Cancer Center, Akashi, Hyogo, Japan; National Shikoku Cancer Center Hospital, Matsuyama, Ehime, Japan; Tokyo-West Tokushukai Hospital, Akishima, Tokyo, Japan; Tonan Hospital, Sapporo, Hokkaido, Japan; Yokohama City University, Yokohama, Kanagawa, Japan; Kyushu University, Fukuoka, Japan; Saitama Medical University International Medical Center, Hidaka, Saitama, Japan
| | - K Nishio
- Kindai University Faculty of Medicine, Osakasayama, Osaka, Japan; Toranomon Hospital, Minato, Tokyo, Japan; Respiratory Medicine, Kanazawa University Hospital, Kanazawa, Ishikawa, Japan; NHO Hokkaido Cancer Center, Sapporo, Hokaido, Japan; Cancer Institute Hospital, Japanese Foundation for Cancer Research, Kotoh, Tokyo, Japan; Hyogo Cancer Center, Akashi, Hyogo, Japan; National Shikoku Cancer Center Hospital, Matsuyama, Ehime, Japan; Tokyo-West Tokushukai Hospital, Akishima, Tokyo, Japan; Tonan Hospital, Sapporo, Hokkaido, Japan; Yokohama City University, Yokohama, Kanagawa, Japan; Kyushu University, Fukuoka, Japan; Saitama Medical University International Medical Center, Hidaka, Saitama, Japan
| |
Collapse
|
15
|
Segi Y, Hashimoto A, Yukimoto H, Yoshizawa N, Aoki M, Fuke H, Kawabata H, Shimizu A, Ichikawa K, Nakano H. A case report of adenosquamous cell carcinoma of the duodenal papilla. Nihon Shokakibyo Gakkai Zasshi 2016; 113:2067-2074. [PMID: 27916775 DOI: 10.11405/nisshoshi.113.2067] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
Adenosquamous carcinoma of the duodenal papilla is rare. A 73-year-old man was referred to the Saiseikai-Matsusaka General Hospital with upper abdominal pain and liver dysfunction. Computed tomography (CT) revealed dilatation of the common bile duct (CBD) and intrahepatic bile duct along with a tumor in the distal CBD. The tumor showed enhancement in the arterial phase on contrast-enhanced CT. We performed endoscopic retrograde cholangiopancreatography and noted a red, erosive, bleeding mass in the duodenal papilla with obstruction of the distal CBD, and dilatation of the CBD. Histopathological inspection of a biopsy of the duodenal papilla showed a mixture of adenocarcinoma and squamous cell carcinoma, suggesting the presence of adenosquamous cell carcinoma in the duodenal papilla. Abdominal examinations including positron emission tomography/CT showed no metastasis or lymph node swelling. The clinical stage was determined to be cT2N0M0 Stage IB. We performed subtotal stomach-preserving pancreaticoduodenectomy. Histopathological inspection of the specimen showed a mixture of adenocarcinoma and squamous cell carcinoma, and squamous cell carcinoma accounted for 40% of the tumor. The tumor was defined as pathological Stage IIA, AcbBd, mixed type, med, pT3b, sci, INFb, ly2, v1, ne2, pN1, HM0, PM0, EM0, PV0, A0, R0, pT3N0M0. We suggested adjuvant chemotherapy, but the patient declined adjuvant chemotherapy and wished to be discharged. Abdominal ultrasonography revealed multiple liver metastases 3 months postoperatively. The patient opted for best supportive care and died 9 months postoperatively. Examination of 23 reports of adenosquamous cell carcinoma of the duodenal papilla in Japan suggested that adenosquamous cell carcinoma of the duodenal papilla has a poorer prognosis compared with adenocarcinoma of the duodenal papilla. Some reports have stated that the growth rate is faster for squamous cell carcinoma than for adenocarcinoma. In our case, the tumor was enhanced in the arterial phase and this represents a feature of adenosquamous cell carcinoma of the duodenal papilla. Chemotherapy has not been established for adenosquamous cell carcinoma of the duodenal papilla. We are confident that we can establish effective chemotherapies in the future.
Collapse
Affiliation(s)
- Yuki Segi
- Department of Internal Medicine, Saiseikai-Matsusaka General Hospital
| | | | | | | | | | | | | | | | | | | |
Collapse
|
16
|
Kikuchi Y, Uchida Y, Kanauchi H, Niwa T, Nishioka K, Tada K, Hashimoto M, Yasuda H, Kawabata H, Seto Y, Ogawa T. 135P A multicenter retrospective observation study about overall survival benefit of eribulin mesylate in comparison with taxane regimens for metastatic cancer patients. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw577.018] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
17
|
Kikuchi Y, Uchida Y, Kanauchi H, Niwa T, Nishioka K, Tada K, Hashimoto M, Yasuda H, Kawabata H, Seto Y, Ogawa T. 135P A multicenter retrospective observation study about overall survival benefit of eribulin mesylate in comparison with taxane regimens for metastatic cancer patients. Ann Oncol 2016. [DOI: 10.1016/s0923-7534(21)00293-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
|
18
|
Tanabe Y, Shiraishi S, Nishizawa D, Hamada A, Hasegawa J, Ozaki Y, Tamura N, Shimomura A, Yunokawa M, Yonemori K, Takano T, Kawabata H, Ikeda K, Tamura K, Fujiwara Y, Shimizu C. Paclitaxel-induced sensory peripheral neuropathy is associated with a SCN9A variant. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw363.85] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
19
|
Suzuki J, Hashino M, Matsumoto S, Takano A, Kawabata H, Takada N, Andoh M, Oikawa Y, Kajita H, Uda A, Watanabe K, Shimizu T, Watarai M. Detection of Francisella tularensis and analysis of bacterial growth in ticks in Japan. Lett Appl Microbiol 2016; 63:240-6. [PMID: 27432517 DOI: 10.1111/lam.12616] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/17/2016] [Revised: 07/13/2016] [Accepted: 07/14/2016] [Indexed: 11/28/2022]
Abstract
UNLABELLED Francisella tularensis is distributed in the Northern hemisphere and it is the bacterial agent responsible for tularaemia, a zoonotic disease. We collected 4 527 samples of DNA from ticks in Japan, which were then analysed by real-time PCR and nested PCR. Francisella DNA was detected by real-time PCR in 2·15% (45/2 093) of Ixodes ovatus, 0·66% (14/2 107) of I. persulcatus, 8·22% (6/73) of I. monospinosus and 0·72% (1/138) of Haemaphysalis flava specimens. Finally, Francisella DNA was detected by nested PCR in 42 and five samples I. ovatus and I. persulcatus, respectively, which were positive according to real-time PCR. Phylogenetic analysis showed that the sequence from I. ovatus and I. persulcatus were clustered with F. tularensis type B strains distributed in Eurasia. Microinjected live F. tularensis persisted in ticks, whereas heat-killed F. tularensis decreased. Microinjected F. tularensis hlyD mutant decreased in ticks significantly compared to parent strain, thereby suggesting that HlyD in F. tularensis contributes to the adaptation or survive of bacterial infection in ticks. SIGNIFICANCE AND IMPACTS OF THE STUDY Francisella tularensis has been detected in ticks, suggesting that it is a tick-borne pathogen. However, F. tularensis has not been detected in ticks in Japan since 1991. In this study, we performed a large-scale analysis of DNA isolated from ticks in Japan and detected F. tularensis by real-time polymerase chain reaction (PCR) and nested PCR. We found that F. tularensis could survive in ticks based on an experimental tick-infection model. We also identified a bacterial factor that contributes to survival in ticks. Our results suggest that ticks are candidate vectors that mediate F. tularensis infection in Japan.
Collapse
Affiliation(s)
- J Suzuki
- The United Graduate School of Veterinary Science, Yamaguchi University, Yamaguchi, Japan
| | - M Hashino
- The United Graduate School of Veterinary Science, Yamaguchi University, Yamaguchi, Japan
| | - S Matsumoto
- Department of Veterinary Medicine, Joint Faculty of Veterinary Medicine, Yamaguchi University, Yamaguchi, Japan
| | - A Takano
- The United Graduate School of Veterinary Science, Yamaguchi University, Yamaguchi, Japan.,Department of Veterinary Medicine, Joint Faculty of Veterinary Medicine, Yamaguchi University, Yamaguchi, Japan
| | - H Kawabata
- Laboratory of Systemic Infection, Department of Bacteriology-I, National Institute of Infectious Diseases, Tokyo, Japan
| | - N Takada
- Faculty of Medical Science, University of Fukui, Eiheiji, Fukui, Japan
| | - M Andoh
- Joint Faculty of Veterinary Medicine, Kagoshima University, Kagoshima, Japan
| | - Y Oikawa
- Department of Medical Zoology, Kanazawa Medical University, Kahoku, Ishikawa, Japan
| | - H Kajita
- Meat Inspection Center of Iwate Prefecture, Iwate, Japan
| | - A Uda
- Department of Veterinary Science, National Institute of Infectious Diseases, Tokyo, Japan
| | - K Watanabe
- The United Graduate School of Veterinary Science, Yamaguchi University, Yamaguchi, Japan.,Department of Veterinary Medicine, Joint Faculty of Veterinary Medicine, Yamaguchi University, Yamaguchi, Japan
| | - T Shimizu
- The United Graduate School of Veterinary Science, Yamaguchi University, Yamaguchi, Japan.,Department of Veterinary Medicine, Joint Faculty of Veterinary Medicine, Yamaguchi University, Yamaguchi, Japan
| | - M Watarai
- The United Graduate School of Veterinary Science, Yamaguchi University, Yamaguchi, Japan. .,Department of Veterinary Medicine, Joint Faculty of Veterinary Medicine, Yamaguchi University, Yamaguchi, Japan.
| |
Collapse
|
20
|
Suissa S, Baker N, Kawabata H, Ray N, Simon T. SAT0150 Comparative Risk of Malignancy with Initiaton of Abatacept and Other Biologics in Patients with Rheumatoid Arthritis: A Cohort Analysis of A United States Claims Database. Ann Rheum Dis 2016. [DOI: 10.1136/annrheumdis-2016-eular.1275] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
21
|
Baker N, Boers M, Hochberg M, Kawabata H, Ray N, Simon T. FRI0229 Risk of Hospitalized Infections in Patients with Rheumatoid Arthritis Initiating Abatacept and Other Biologics: Analysis of A United States Claims Database. Ann Rheum Dis 2016. [DOI: 10.1136/annrheumdis-2016-eular.1322] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
22
|
Ishiyama K, Takeda J, Kondo T, Sugimoto N, Kawabata H, Kitano T, Takaori-Kondo A. Feasibility of salvage cord blood transplantation following fludarabine, melphalan and low-dose TBI for graft rejection after hematopoietic stem cell transplantation. Bone Marrow Transplant 2016; 51:985-7. [PMID: 26878662 DOI: 10.1038/bmt.2016.16] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- K Ishiyama
- Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan
| | - J Takeda
- Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan
| | - T Kondo
- Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan
| | - N Sugimoto
- Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.,Department of Clinical Application, Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto, Japan
| | - H Kawabata
- Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan
| | - T Kitano
- Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan
| | - A Takaori-Kondo
- Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan
| |
Collapse
|
23
|
Ozaki Y, Tamura N, Utiyama M, Masuda J, Koganemaru S, Miura Y, Tanabe Y, Ogura T, Kadowaki M, Miura D, Kawabata H, Takano T. Abstract P5-12-11: Duration of ovarian function suppression for premenopausal women with hormone receptor-positive breast cancer: Retrospective study. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p5-12-11] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Although tamoxifen (TAM) plus ovarian function suppression (OFS) is one of standard adjuvant treatments in premenopausal women with hormone receptor-positive breast cancer, the optimal duration of OFS has not been clearly established.
Patients and Methods: We retrospectively reviewed data of premenopausal patients with breast cancer, who received TAM and OFS (goserelin or leuprorelin) as adjuvant therapy between February 2004 and April 2015. The primary analysis was to compare disease-free survival (DFS) between patients who received OFS shorter than 3 years and those who received OFS longer than 3 years. The analyses were performed with Cox proportional hazards models and propensity score matching models.
Results: We analyzed 206 premenopausal patients with hormone receptor-positive breast cancer. Median follow-up time was 56 months. Median age was 42 years (range, 24-52 years). Twenty six per cent of the patients had positive axillary nodes and 30% had received neo-adjuvant or adjuvant chemotherapy. Median duration of OFS was 26 months. Duration of OFS was shorter than three years (OFS < 3y) in 74% patients, and longer than three years (OFS > 3y) in 26% patients. Patients with node-positive disease were more in OFS > 3y group than in OFS < 3y group, and more patients received chemotherapy in OFS > 3y group than in OFS < 3y group. 5-year disease-free survival (DFS) was 96.1%. DFS in patients aged ≤ 40 years and aged > 40 years were 91.8% and 99.0%, respectively (p=0.0223). Propensity score matching model showed that DFS was not significantly different between patients in OFS < 3y group and those in OFS > 3y group (97.4%, 91.6%; p=0.2406). In patients aged ≤ 40 years and/or those who received chemotherapy, 5-year DFS was 96.7% in OFS < 3y group, 90.1% in OFS > 3y group (p=0.3011).
Conclusions: Our data suggest that OFS < 3y is not inferior to OFS > 3y for premenopausal women with hormone receptor-positive breast cancer as adjuvant endocrine therapy. A randomized trial is needed to establish the optimal OFS duration for these patients.
Citation Format: Ozaki Y, Tamura N, Utiyama M, Masuda J, Koganemaru S, Miura Y, Tanabe Y, Ogura T, Kadowaki M, Miura D, Kawabata H, Takano T. Duration of ovarian function suppression for premenopausal women with hormone receptor-positive breast cancer: Retrospective study. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P5-12-11.
Collapse
Affiliation(s)
- Y Ozaki
- Toranomon Hospital, 2-2-2 Toranomon Minato-ku, Tokyo, Japan
| | - N Tamura
- Toranomon Hospital, 2-2-2 Toranomon Minato-ku, Tokyo, Japan
| | - M Utiyama
- Toranomon Hospital, 2-2-2 Toranomon Minato-ku, Tokyo, Japan
| | - J Masuda
- Toranomon Hospital, 2-2-2 Toranomon Minato-ku, Tokyo, Japan
| | - S Koganemaru
- Toranomon Hospital, 2-2-2 Toranomon Minato-ku, Tokyo, Japan
| | - Y Miura
- Toranomon Hospital, 2-2-2 Toranomon Minato-ku, Tokyo, Japan
| | - Y Tanabe
- Toranomon Hospital, 2-2-2 Toranomon Minato-ku, Tokyo, Japan
| | - T Ogura
- Toranomon Hospital, 2-2-2 Toranomon Minato-ku, Tokyo, Japan
| | - M Kadowaki
- Toranomon Hospital, 2-2-2 Toranomon Minato-ku, Tokyo, Japan
| | - D Miura
- Toranomon Hospital, 2-2-2 Toranomon Minato-ku, Tokyo, Japan
| | - H Kawabata
- Toranomon Hospital, 2-2-2 Toranomon Minato-ku, Tokyo, Japan
| | - T Takano
- Toranomon Hospital, 2-2-2 Toranomon Minato-ku, Tokyo, Japan
| |
Collapse
|
24
|
Masuda J, Ozaki Y, Nakajima H, Oki R, Uchiyama M, Koganemaru S, Ogura T, Tamura N, Miura Y, Tanabe Y, Miura D, Kawabata H, Takano T. 104P Feasibility of dose-dense doxorubicin and cyclophosphamide (ddAC) followed by taxane (T) in Japanese women with early breast cancer: A retrospective study. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv519.53] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
25
|
Murakami Y, Kawabata H, Takeuchi Y, Doi Y, Okabe T, Kenjo M, Kimura T, Nagata Y. Incidence and Clinical Features of Metachronous Esophageal Cancer After Definitive Radiation Therapy for Esophageal Cancer. Int J Radiat Oncol Biol Phys 2015. [DOI: 10.1016/j.ijrobp.2015.07.861] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
26
|
Kubo K, Kimura T, Sakaguchi H, Imano N, Kawabata H, Takeuchi Y, Doi Y, Okabe T, Kenjo M, Ozawa S, Murakami Y, Nagata Y. Computed Tomographic Appearance of Radiation Injuries in Lung After Two Prescribed Dose of 48Gy With Stereotactic Body Radiation Therapy. Int J Radiat Oncol Biol Phys 2015. [DOI: 10.1016/j.ijrobp.2015.07.1620] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
27
|
Imano N, Kimura T, Nishibuchi I, Nakashima T, Kubo K, Sakaguchi H, Kawabata H, Takeuchi Y, Doi Y, Okabe T, Kenjo M, Ozawa S, Murakami Y, Nagata Y. A Quantitative Index for Phase Selection in Planning of Respiratory Gating Radiation Therapy for Lung Cancer. Int J Radiat Oncol Biol Phys 2015. [DOI: 10.1016/j.ijrobp.2015.07.522] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
28
|
Abe K, Iyogi T, Kawabata H, Chiang JH, Suwa H, Hisamatsu S. Estimation of 85Kr dispersion from the spent nuclear fuel reprocessing plant in Rokkasho, Japan, using an atmospheric dispersion model. Radiat Prot Dosimetry 2015; 167:331-335. [PMID: 25948824 DOI: 10.1093/rpd/ncv273] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/04/2023]
Abstract
The spent nuclear fuel reprocessing plant of Japan Nuclear Fuel Limited (JNFL) located in Rokkasho, Japan, discharged small amounts of (85)Kr into the atmosphere during final tests of the plant with actual spent fuel from 31 March 2006 to October 2008. During this period, the gamma-ray dose rates due to discharged (85)Kr were higher than the background rates measured at the Institute for Environmental Sciences and at seven monitoring stations of the Aomori prefectural government and JNFL. The dispersion of (85)Kr was simulated by means of the fifth-generation Penn State/NCAR Mesoscale Model and the CG-MATHEW/ADPIC models (ver. 5.0) with a vertical terrain-following height coordinate. Although the simulated gamma-ray dose rates due to discharged (85)Kr agreed fairly well with measured rates, the agreement between the estimated monthly mean (85)Kr concentrations and the observed concentrations was poor. Improvement of the vertical flow of air may lead to better estimation of (85)Kr dispersion.
Collapse
Affiliation(s)
- K Abe
- Institute for Environmental Sciences, 1-7 Ienomae, Obuchi, Rokkasho, Aomori, Japan
| | - T Iyogi
- Institute for Environmental Sciences, 1-7 Ienomae, Obuchi, Rokkasho, Aomori, Japan
| | - H Kawabata
- Institute for Environmental Sciences, 1-7 Ienomae, Obuchi, Rokkasho, Aomori, Japan
| | - J H Chiang
- Japan NUS Co. Ltd., Nishi-Shinjuku Kimuraya Building 5F, 7-5-25 Nishi-Shinjuku, Shinjuku-ku, Tokyo, Japan
| | - H Suwa
- Japan NUS Co. Ltd., Nishi-Shinjuku Kimuraya Building 5F, 7-5-25 Nishi-Shinjuku, Shinjuku-ku, Tokyo, Japan
| | - S Hisamatsu
- Institute for Environmental Sciences, 1-7 Ienomae, Obuchi, Rokkasho, Aomori, Japan
| |
Collapse
|
29
|
Takeuchi Y, Murakami Y, Kubo K, Sakaguchi H, Imano N, Kawabata H, Doi Y, Okabe T, Kenjo M, Kimura T, Nagata Y, Fujita M, Konishi M. Interstitial Brachytherapy for Early-Stage Tongue Cancer: Analysis of the Long-term Treatment Results for Survival and Complications. Int J Radiat Oncol Biol Phys 2015. [DOI: 10.1016/j.ijrobp.2015.07.1303] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
30
|
Simon T, Kawabata H, Esdaile J, Moorthy V, Suissa S. FRI0371 Autoimmune Diseases in Patients with Rheumatoid Arthritis. Ann Rheum Dis 2015. [DOI: 10.1136/annrheumdis-2015-eular.2841] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
31
|
Suissa S, Baker N, Ravindran A, Kawabata H, Simon T. THU0366 Characteristics of Patients Initiating Abatacept for the Treatment of Rheumatoid Arthritis in the Real World: Methodological Challenges for Comparative Safety Studies. Ann Rheum Dis 2015. [DOI: 10.1136/annrheumdis-2015-eular.1850] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
32
|
Baker N, Suissa S, Kawabata H, Skovron M, Moorthy V, Simon T. AB0474 Identification of Tuberculosis Incidence Through the Use of a Validated Claims-Based Algorithm Among Rheumatoid Arthritis Patients Treated with Disease-Modifying Antirheumatic Drugs. Ann Rheum Dis 2015. [DOI: 10.1136/annrheumdis-2015-eular.1610] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
33
|
Kachroo S, Pan X, Liu L, Kawabata H, Phatak H. Clinical and Demographics Characteristics of Non-Valvular Atrial Fibrillation Patients Switching From Warfarin To Novel Oral Anticoagulants. Value Health 2014; 17:A500-A501. [PMID: 27201512 DOI: 10.1016/j.jval.2014.08.1506] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/05/2023]
Affiliation(s)
- S Kachroo
- Bristol-Myers Squibb Company, Princeton, NJ, USA
| | - X Pan
- Bristol-Myers Squibb, New Haven, CT, USA
| | - L Liu
- Pfizer, New York, NY, USA
| | | | - H Phatak
- Bristol-Myers Squibb Company, Princeton, NJ, USA
| |
Collapse
|
34
|
Kawakami M, Sato S, Miyabe Y, Tanabe K, Nishimura M, Tsuji M, Murakami Y, Kawabata H, Fushiki M. Development of Error Estimating Program for IMRT Dose Delivery Using Dynamic MLC Log Files. Int J Radiat Oncol Biol Phys 2014. [DOI: 10.1016/j.ijrobp.2014.05.2476] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
35
|
Hidano A, Konnai S, Yamada S, Githaka N, Isezaki M, Higuchi H, Nagahata H, Ito T, Takano A, Ando S, Kawabata H, Murata S, Ohahsi K. Suppressive effects of neutrophil by Salp16-like salivary gland proteins from Ixodes persulcatus Schulze tick. Insect Mol Biol 2014; 23:466-474. [PMID: 24698498 DOI: 10.1111/imb.12101] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
Abstract
Salp16, a 16-kDa tick salivary gland protein, is known to be the molecule involved in the transmission of Anaplasma phagocytophilum, an obligate intracellular pathogen causing zoonotic anaplasmosis, from its mammalian hosts to Ixodes scapularis. Recently, the presence of A. phagocytophilum was documented in Japan and Ixodes persulcatus was identified as one of its vectors. The purpose of this study was to identify Salp16 genes in I. persulcatus and characterize their function. Two cDNA clones encoding the Salp16-like sequences were obtained from the salivary glands of fed female I. persulcatus ticks and designated Salp16 Iper1 and Iper2. Gene expression analyses showed that the Salp16 Iper genes were expressed specifically in the salivary glands and were up-regulated by blood feeding. These proteins attenuated the oxidative burst of activated bovine neutrophils and inhibited their migration induced by the chemoattractant interleukin-8 (IL-8). These results demonstrate that Salp16 Iper proteins contribute to the establishment of blood feeding as an immunosuppressant of neutrophil, an essential factor in innate host immunity. Further examination of the role of Salp16 Iper in the transmission of pathogens, including A. phagocytophilum, will increase our understanding of the tick-host-pathogen interface.
Collapse
Affiliation(s)
- A Hidano
- Department of Disease Control, Graduate School of Veterinary Medicine, Hokkaido University, Sapporo, Japan
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
36
|
Alemao E, Joo S, Kawabata H, Al M, Allison P, Rutten-van Molken M, Frits M, Iannaccone C, Shadick N, Weinblatt M. THU0246 Differences (OR Variations) in Physical Functioning in RA by Disease Activity Levels Defined by Das, CDai, and SDAI in Clinical Practice. Ann Rheum Dis 2014. [DOI: 10.1136/annrheumdis-2014-eular.1519] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
37
|
Rajagopalan V, Alemao E, Kawabata H, Solomon D. SAT0069 Performance of the Framingham Cardiovascular Risk Prediction Model with and without C-Reactive Protein or Erythrocyte Sedimentation Rate in RA: Analysis of US Electronic Medical Records Database. Ann Rheum Dis 2014. [DOI: 10.1136/annrheumdis-2014-eular.1833] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
38
|
An J, Alemao E, Cheetham T, Reynolds K, Kawabata H, Solomon D. SAT0044 The Role of C-Reactive Protein or Erythrocyte Sedimentation Rate in Predicting Cardiovascular Outcomes in Rheumatoid Arthritis: Analysis of Data from US Managed Care Organization. Ann Rheum Dis 2014. [DOI: 10.1136/annrheumdis-2014-eular.1742] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
39
|
Alemao E, Joo S, Kawabata H, Al M, Allison P, Rutten-van Molken M, Frits M, Iannaccone C, Shadick N, Weinblatt M. FRI0003 Quality of Life and Economic Benefits of Remission/Low Disease Activity in Patients with Rheumatoid Arthritis in Clinical Practice Setting. Ann Rheum Dis 2014. [DOI: 10.1136/annrheumdis-2014-eular.1897] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
40
|
Takada M, Ishiguro H, Nagai S, Ohtani S, Kawabata H, Yanagita Y, Hozumi Y, Shimizu C, Takao S, Sato N, Kosaka Y, Sagara Y, Iwata H, Ohno S, Kuroi K, Masuda N, Yamashiro H, Sugimoto M, Kondo M, Naito Y, Sasano H, Inamoto T, Morita S, Toi M. Survival of HER2-positive primary breast cancer patients treated by neoadjuvant chemotherapy plus trastuzumab: a multicenter retrospective observational study (JBCRG-C03 study). Breast Cancer Res Treat 2014; 145:143-53. [PMID: 24682674 DOI: 10.1007/s10549-014-2907-9] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/03/2014] [Accepted: 03/04/2014] [Indexed: 10/25/2022]
Abstract
We investigated the disease-free survival (DFS) of HER2-positive primary breast cancer patients treated with neoadjuvant chemotherapy plus trastuzumab, as well as predictive factors for DFS and pathologic response. Data from 829 female patients treated between 2001 and 2010 were collected from 38 institutions in Japan. Predictive factors were evaluated using multivariate analyses. The 3-year DFS rate was 87 % [95 % confidence interval (CI) 85-90]. The pathologic complete response (pCR: ypT0/is + ypN0) rate was 51 %. The pCR rate was higher in the ER/PgR-negative patients than in the ER/PgR-positive patients (64 vs. 36 %, P < 0.001). Patients with pCR showed a higher DFS rate than patients without pCR (93 vs. 82 %, P < 0.001). Multivariate analysis revealed three independent predictors for poorer DFS: advanced nodal stage [hazard ratio (HR) 2.63, 95 % CI 1.36-5.21, P = 0.004 for cN2-3 vs. cN0], histological/nuclear grade 3 (HR 1.81, 95 % CI 1.15-2.91, P = 0.011), and non-pCR (HR 1.98, 95 % CI 1.22-3.24, P = 0.005). In the ER/PgR-negative dataset, non-pCR (HR 2.63, 95 % CI 1.43-4.90, P = 0.002) and clinical tumor stage (HR 2.20, 95 % CI 1.16-4.20, P = 0.017 for cT3-4 vs. cT1-2) were independent predictors for DFS, and in the ER/PgR-positive dataset, histological grade of 3 (HR 3.09, 95 % CI 1.48-6.62, P = 0.003), clinical nodal stage (HR 4.26, 95 % CI 1.53-13.14, P = 0.005 for cN2-3 vs. cN0), and young age (HR 2.40, 95 % CI 1.12-4.94, P = 0.026 for ≤40 vs. >40) were negative predictors for DFS. Strict pCR (ypT0 + ypN0) was an independent predictor for DFS in both the ER/PgR-negative and -positive datasets (HR 2.66, 95 % CI 1.31-5.97, P = 0.006 and HR 3.86, 95 % CI 1.13-24.21, P = 0.029, respectively). These results may help assure a more accurate prognosis and personalized treatment for HER2-positive breast cancer patients.
Collapse
Affiliation(s)
- M Takada
- Department of Breast Surgery, Graduate School of Medicine, Kyoto University, 54 Kawaracho, Shogoin, Sakyo-ku, Kyoto, 606-8507, Japan
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
41
|
Takada M, Ishiguro H, Nagai S, Ohtani S, Kawabata H, Yanagita Y, Hozumi Y, Shimizu C, Takao S, Sato N, Kosaka Y, Sagara Y, Iwata H, Ohno S, Kuroi K, Masuda N, Yamashiro H, Sugimoto M, Kondo M, Naito Y, Sasano H, Inamoto T, Morita S, Toi M. Abstract P6-06-20: Predictive factors for pathologic complete response and disease-free survival after neoadjuvant chemotherapy with trastuzumab: A multicenter retrospective observational study in patients with HER2-positive primary breast cancer (JBCRG-C03 study). Cancer Res 2013. [DOI: 10.1158/0008-5472.sabcs13-p6-06-20] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
BACKGROUND:
Addition of trastuzumab to neoadjuvant chemotherapy (NAC) improved pathologic complete response (pCR) rate in HER2-positive breast cancer. Although recent trials have shown favorable prognosis with NAC plus trastuzumab, clinicopathological factors to predict the outcome have not been fully understood. The aim of this study was to investigate the survival after NAC with trastuzumab and to explore the predictive factors.
PATIENTS AND METHODS:
This is a multicenter retrospective observational study. Patients with HER2-positive primary breast cancer treated with NAC plus trastuzumab from 2001 to 2010 were identified from the institutional database. Primary end point was disease-free survival (DFS). pCR was defined as ypT0/is+ypN0. Kaplan-Meier method was used to estimate DFS. Logistic regression and proportional hazard analysis were used to identify clinicopathological factors to predict pCR and DFS, respectively.
RESULTS:
733 patients were included in the analysis (whole dataset). 425 were ER/PgR-negative (HR- dataset) and 306 were ER/PgR-positive (HR+ dataset). Radiation therapy was performed in 90% of lumpectomy and 31% of mastectomy. Hormonal therapy was performed in 84% of HR+ dataset. pCR rate was 45% in whole dataset, 60% in HR- dataset, and 34% in HR+ dataset. Table 1 showed the result of multivariate analysis for pCR in whole dataset. When HR+ and HR- dataset were analyzed separately, no definitive predictors for pCR were identified in multivariate analysis. Although the patients with pCR showed a significantly favorable prognosis than those without pCR at 3 years DFS, in whole dataset (93% vs 83%, p<0.0001) and HR- dataset (94% vs 80%, p<0.0001), there was no significant difference in HR+ dataset (89% vs 86%, p = 0.10). Different predictors were selected for DFS when multivariate analysis was conducted separately between HR- and HR+ dataset (Table 2).
CONCLUSIONS:
In this observational study, we clarified predictors for pCR and DFS in HER2-positive patients treated with neoadjuvant trastuzumab containing therapy based on tumor subtype. Our results may help us to predict the prognosis more precisely and to simulate the disease course.
Table 1) Multivariate logistic regression analysis for pCR in whole datasetFactorsOR95%CIp-valuePost- vs Pre-menopause1.50(1.05-2.15)0.026*cT1-2 vs cT3-41.72(1.16-2.59)0.008*ER/PgR-negative vs ER/PgR-positive3.32(2.30-4.82)<0.0001*Grade 3 vs 1-21.28(0.89-1.84)0.183
Table 2) Multivariate proportional hazard analysis for DFSFactors†HR95%CIp-valueWhole dataset Pre- vs Post-menopause1.61(1.04-2.52)0.033*cN2-3 vs cN03.06(1.58-6.24)0.001*cN1 vs cN02.26(1.23-4.41)0.007*Grade 3 vs 1-21.87(1.20-2.97)0.006*non-pCR vs pCR1.90(1.18-3.13)0.008*HR- dataset Pre- vs Post-menopause1.70(1.01-2.85)0.046*cT3-4 vs cT1-21.86(1.09-3.17)0.024*non-pCR vs pCR3.28(1.90-5.87)<0.0001*HR+ dataset cN2-3 vs cN05.01(1.79-16.19)0.002*cN1 vs cN03.50(1.40-10.61)0.006*Grade 3 vs 1-22.95(1.52-5.87)0.001*†Only factors with statistical significance
Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P6-06-20.
Collapse
Affiliation(s)
- M Takada
- Kyoto University Hospital, Kyoto, Japan; Kyoto University Hospital; Saitama Cancer Center; Hiroshima City Hospital; Toranomon Hospital; Gunma Prefectural Cancer Center; Jichi Medical University Hospital; National Cancer Center Hospital; Hyogo Cancer Center; Niigata Cancer Center Hospital; Kitasato University School of Medicine; Social Medical Corporation Hakuaikai, Sagara Hospital; Aichi Cancer Center; Clinical Cancer Center, National Kyushu Cancer Center; Tokyo Metropolitan Cancer and Infectious Diseases Centre, Komagome Hospital; Osaka National Hospital; National Hospital Organization Kure Medical Center; Institute for Advanced Biosciences, Keio University; Faculty of Medicine, University of Tsukuba; Keio University; Tohoku University Hospital and School of Medicine; Faculty of Health Care, Tenri Health Care University; Institute for Advancement of Clinical and Translational Science, Kyoto University Hospital; Graduate School of Medicine, Kyoto University
| | - H Ishiguro
- Kyoto University Hospital, Kyoto, Japan; Kyoto University Hospital; Saitama Cancer Center; Hiroshima City Hospital; Toranomon Hospital; Gunma Prefectural Cancer Center; Jichi Medical University Hospital; National Cancer Center Hospital; Hyogo Cancer Center; Niigata Cancer Center Hospital; Kitasato University School of Medicine; Social Medical Corporation Hakuaikai, Sagara Hospital; Aichi Cancer Center; Clinical Cancer Center, National Kyushu Cancer Center; Tokyo Metropolitan Cancer and Infectious Diseases Centre, Komagome Hospital; Osaka National Hospital; National Hospital Organization Kure Medical Center; Institute for Advanced Biosciences, Keio University; Faculty of Medicine, University of Tsukuba; Keio University; Tohoku University Hospital and School of Medicine; Faculty of Health Care, Tenri Health Care University; Institute for Advancement of Clinical and Translational Science, Kyoto University Hospital; Graduate School of Medicine, Kyoto University
| | - S Nagai
- Kyoto University Hospital, Kyoto, Japan; Kyoto University Hospital; Saitama Cancer Center; Hiroshima City Hospital; Toranomon Hospital; Gunma Prefectural Cancer Center; Jichi Medical University Hospital; National Cancer Center Hospital; Hyogo Cancer Center; Niigata Cancer Center Hospital; Kitasato University School of Medicine; Social Medical Corporation Hakuaikai, Sagara Hospital; Aichi Cancer Center; Clinical Cancer Center, National Kyushu Cancer Center; Tokyo Metropolitan Cancer and Infectious Diseases Centre, Komagome Hospital; Osaka National Hospital; National Hospital Organization Kure Medical Center; Institute for Advanced Biosciences, Keio University; Faculty of Medicine, University of Tsukuba; Keio University; Tohoku University Hospital and School of Medicine; Faculty of Health Care, Tenri Health Care University; Institute for Advancement of Clinical and Translational Science, Kyoto University Hospital; Graduate School of Medicine, Kyoto University
| | - S Ohtani
- Kyoto University Hospital, Kyoto, Japan; Kyoto University Hospital; Saitama Cancer Center; Hiroshima City Hospital; Toranomon Hospital; Gunma Prefectural Cancer Center; Jichi Medical University Hospital; National Cancer Center Hospital; Hyogo Cancer Center; Niigata Cancer Center Hospital; Kitasato University School of Medicine; Social Medical Corporation Hakuaikai, Sagara Hospital; Aichi Cancer Center; Clinical Cancer Center, National Kyushu Cancer Center; Tokyo Metropolitan Cancer and Infectious Diseases Centre, Komagome Hospital; Osaka National Hospital; National Hospital Organization Kure Medical Center; Institute for Advanced Biosciences, Keio University; Faculty of Medicine, University of Tsukuba; Keio University; Tohoku University Hospital and School of Medicine; Faculty of Health Care, Tenri Health Care University; Institute for Advancement of Clinical and Translational Science, Kyoto University Hospital; Graduate School of Medicine, Kyoto University
| | - H Kawabata
- Kyoto University Hospital, Kyoto, Japan; Kyoto University Hospital; Saitama Cancer Center; Hiroshima City Hospital; Toranomon Hospital; Gunma Prefectural Cancer Center; Jichi Medical University Hospital; National Cancer Center Hospital; Hyogo Cancer Center; Niigata Cancer Center Hospital; Kitasato University School of Medicine; Social Medical Corporation Hakuaikai, Sagara Hospital; Aichi Cancer Center; Clinical Cancer Center, National Kyushu Cancer Center; Tokyo Metropolitan Cancer and Infectious Diseases Centre, Komagome Hospital; Osaka National Hospital; National Hospital Organization Kure Medical Center; Institute for Advanced Biosciences, Keio University; Faculty of Medicine, University of Tsukuba; Keio University; Tohoku University Hospital and School of Medicine; Faculty of Health Care, Tenri Health Care University; Institute for Advancement of Clinical and Translational Science, Kyoto University Hospital; Graduate School of Medicine, Kyoto University
| | - Y Yanagita
- Kyoto University Hospital, Kyoto, Japan; Kyoto University Hospital; Saitama Cancer Center; Hiroshima City Hospital; Toranomon Hospital; Gunma Prefectural Cancer Center; Jichi Medical University Hospital; National Cancer Center Hospital; Hyogo Cancer Center; Niigata Cancer Center Hospital; Kitasato University School of Medicine; Social Medical Corporation Hakuaikai, Sagara Hospital; Aichi Cancer Center; Clinical Cancer Center, National Kyushu Cancer Center; Tokyo Metropolitan Cancer and Infectious Diseases Centre, Komagome Hospital; Osaka National Hospital; National Hospital Organization Kure Medical Center; Institute for Advanced Biosciences, Keio University; Faculty of Medicine, University of Tsukuba; Keio University; Tohoku University Hospital and School of Medicine; Faculty of Health Care, Tenri Health Care University; Institute for Advancement of Clinical and Translational Science, Kyoto University Hospital; Graduate School of Medicine, Kyoto University
| | - Y Hozumi
- Kyoto University Hospital, Kyoto, Japan; Kyoto University Hospital; Saitama Cancer Center; Hiroshima City Hospital; Toranomon Hospital; Gunma Prefectural Cancer Center; Jichi Medical University Hospital; National Cancer Center Hospital; Hyogo Cancer Center; Niigata Cancer Center Hospital; Kitasato University School of Medicine; Social Medical Corporation Hakuaikai, Sagara Hospital; Aichi Cancer Center; Clinical Cancer Center, National Kyushu Cancer Center; Tokyo Metropolitan Cancer and Infectious Diseases Centre, Komagome Hospital; Osaka National Hospital; National Hospital Organization Kure Medical Center; Institute for Advanced Biosciences, Keio University; Faculty of Medicine, University of Tsukuba; Keio University; Tohoku University Hospital and School of Medicine; Faculty of Health Care, Tenri Health Care University; Institute for Advancement of Clinical and Translational Science, Kyoto University Hospital; Graduate School of Medicine, Kyoto University
| | - C Shimizu
- Kyoto University Hospital, Kyoto, Japan; Kyoto University Hospital; Saitama Cancer Center; Hiroshima City Hospital; Toranomon Hospital; Gunma Prefectural Cancer Center; Jichi Medical University Hospital; National Cancer Center Hospital; Hyogo Cancer Center; Niigata Cancer Center Hospital; Kitasato University School of Medicine; Social Medical Corporation Hakuaikai, Sagara Hospital; Aichi Cancer Center; Clinical Cancer Center, National Kyushu Cancer Center; Tokyo Metropolitan Cancer and Infectious Diseases Centre, Komagome Hospital; Osaka National Hospital; National Hospital Organization Kure Medical Center; Institute for Advanced Biosciences, Keio University; Faculty of Medicine, University of Tsukuba; Keio University; Tohoku University Hospital and School of Medicine; Faculty of Health Care, Tenri Health Care University; Institute for Advancement of Clinical and Translational Science, Kyoto University Hospital; Graduate School of Medicine, Kyoto University
| | - S Takao
- Kyoto University Hospital, Kyoto, Japan; Kyoto University Hospital; Saitama Cancer Center; Hiroshima City Hospital; Toranomon Hospital; Gunma Prefectural Cancer Center; Jichi Medical University Hospital; National Cancer Center Hospital; Hyogo Cancer Center; Niigata Cancer Center Hospital; Kitasato University School of Medicine; Social Medical Corporation Hakuaikai, Sagara Hospital; Aichi Cancer Center; Clinical Cancer Center, National Kyushu Cancer Center; Tokyo Metropolitan Cancer and Infectious Diseases Centre, Komagome Hospital; Osaka National Hospital; National Hospital Organization Kure Medical Center; Institute for Advanced Biosciences, Keio University; Faculty of Medicine, University of Tsukuba; Keio University; Tohoku University Hospital and School of Medicine; Faculty of Health Care, Tenri Health Care University; Institute for Advancement of Clinical and Translational Science, Kyoto University Hospital; Graduate School of Medicine, Kyoto University
| | - N Sato
- Kyoto University Hospital, Kyoto, Japan; Kyoto University Hospital; Saitama Cancer Center; Hiroshima City Hospital; Toranomon Hospital; Gunma Prefectural Cancer Center; Jichi Medical University Hospital; National Cancer Center Hospital; Hyogo Cancer Center; Niigata Cancer Center Hospital; Kitasato University School of Medicine; Social Medical Corporation Hakuaikai, Sagara Hospital; Aichi Cancer Center; Clinical Cancer Center, National Kyushu Cancer Center; Tokyo Metropolitan Cancer and Infectious Diseases Centre, Komagome Hospital; Osaka National Hospital; National Hospital Organization Kure Medical Center; Institute for Advanced Biosciences, Keio University; Faculty of Medicine, University of Tsukuba; Keio University; Tohoku University Hospital and School of Medicine; Faculty of Health Care, Tenri Health Care University; Institute for Advancement of Clinical and Translational Science, Kyoto University Hospital; Graduate School of Medicine, Kyoto University
| | - Y Kosaka
- Kyoto University Hospital, Kyoto, Japan; Kyoto University Hospital; Saitama Cancer Center; Hiroshima City Hospital; Toranomon Hospital; Gunma Prefectural Cancer Center; Jichi Medical University Hospital; National Cancer Center Hospital; Hyogo Cancer Center; Niigata Cancer Center Hospital; Kitasato University School of Medicine; Social Medical Corporation Hakuaikai, Sagara Hospital; Aichi Cancer Center; Clinical Cancer Center, National Kyushu Cancer Center; Tokyo Metropolitan Cancer and Infectious Diseases Centre, Komagome Hospital; Osaka National Hospital; National Hospital Organization Kure Medical Center; Institute for Advanced Biosciences, Keio University; Faculty of Medicine, University of Tsukuba; Keio University; Tohoku University Hospital and School of Medicine; Faculty of Health Care, Tenri Health Care University; Institute for Advancement of Clinical and Translational Science, Kyoto University Hospital; Graduate School of Medicine, Kyoto University
| | - Y Sagara
- Kyoto University Hospital, Kyoto, Japan; Kyoto University Hospital; Saitama Cancer Center; Hiroshima City Hospital; Toranomon Hospital; Gunma Prefectural Cancer Center; Jichi Medical University Hospital; National Cancer Center Hospital; Hyogo Cancer Center; Niigata Cancer Center Hospital; Kitasato University School of Medicine; Social Medical Corporation Hakuaikai, Sagara Hospital; Aichi Cancer Center; Clinical Cancer Center, National Kyushu Cancer Center; Tokyo Metropolitan Cancer and Infectious Diseases Centre, Komagome Hospital; Osaka National Hospital; National Hospital Organization Kure Medical Center; Institute for Advanced Biosciences, Keio University; Faculty of Medicine, University of Tsukuba; Keio University; Tohoku University Hospital and School of Medicine; Faculty of Health Care, Tenri Health Care University; Institute for Advancement of Clinical and Translational Science, Kyoto University Hospital; Graduate School of Medicine, Kyoto University
| | - H Iwata
- Kyoto University Hospital, Kyoto, Japan; Kyoto University Hospital; Saitama Cancer Center; Hiroshima City Hospital; Toranomon Hospital; Gunma Prefectural Cancer Center; Jichi Medical University Hospital; National Cancer Center Hospital; Hyogo Cancer Center; Niigata Cancer Center Hospital; Kitasato University School of Medicine; Social Medical Corporation Hakuaikai, Sagara Hospital; Aichi Cancer Center; Clinical Cancer Center, National Kyushu Cancer Center; Tokyo Metropolitan Cancer and Infectious Diseases Centre, Komagome Hospital; Osaka National Hospital; National Hospital Organization Kure Medical Center; Institute for Advanced Biosciences, Keio University; Faculty of Medicine, University of Tsukuba; Keio University; Tohoku University Hospital and School of Medicine; Faculty of Health Care, Tenri Health Care University; Institute for Advancement of Clinical and Translational Science, Kyoto University Hospital; Graduate School of Medicine, Kyoto University
| | - S Ohno
- Kyoto University Hospital, Kyoto, Japan; Kyoto University Hospital; Saitama Cancer Center; Hiroshima City Hospital; Toranomon Hospital; Gunma Prefectural Cancer Center; Jichi Medical University Hospital; National Cancer Center Hospital; Hyogo Cancer Center; Niigata Cancer Center Hospital; Kitasato University School of Medicine; Social Medical Corporation Hakuaikai, Sagara Hospital; Aichi Cancer Center; Clinical Cancer Center, National Kyushu Cancer Center; Tokyo Metropolitan Cancer and Infectious Diseases Centre, Komagome Hospital; Osaka National Hospital; National Hospital Organization Kure Medical Center; Institute for Advanced Biosciences, Keio University; Faculty of Medicine, University of Tsukuba; Keio University; Tohoku University Hospital and School of Medicine; Faculty of Health Care, Tenri Health Care University; Institute for Advancement of Clinical and Translational Science, Kyoto University Hospital; Graduate School of Medicine, Kyoto University
| | - K Kuroi
- Kyoto University Hospital, Kyoto, Japan; Kyoto University Hospital; Saitama Cancer Center; Hiroshima City Hospital; Toranomon Hospital; Gunma Prefectural Cancer Center; Jichi Medical University Hospital; National Cancer Center Hospital; Hyogo Cancer Center; Niigata Cancer Center Hospital; Kitasato University School of Medicine; Social Medical Corporation Hakuaikai, Sagara Hospital; Aichi Cancer Center; Clinical Cancer Center, National Kyushu Cancer Center; Tokyo Metropolitan Cancer and Infectious Diseases Centre, Komagome Hospital; Osaka National Hospital; National Hospital Organization Kure Medical Center; Institute for Advanced Biosciences, Keio University; Faculty of Medicine, University of Tsukuba; Keio University; Tohoku University Hospital and School of Medicine; Faculty of Health Care, Tenri Health Care University; Institute for Advancement of Clinical and Translational Science, Kyoto University Hospital; Graduate School of Medicine, Kyoto University
| | - N Masuda
- Kyoto University Hospital, Kyoto, Japan; Kyoto University Hospital; Saitama Cancer Center; Hiroshima City Hospital; Toranomon Hospital; Gunma Prefectural Cancer Center; Jichi Medical University Hospital; National Cancer Center Hospital; Hyogo Cancer Center; Niigata Cancer Center Hospital; Kitasato University School of Medicine; Social Medical Corporation Hakuaikai, Sagara Hospital; Aichi Cancer Center; Clinical Cancer Center, National Kyushu Cancer Center; Tokyo Metropolitan Cancer and Infectious Diseases Centre, Komagome Hospital; Osaka National Hospital; National Hospital Organization Kure Medical Center; Institute for Advanced Biosciences, Keio University; Faculty of Medicine, University of Tsukuba; Keio University; Tohoku University Hospital and School of Medicine; Faculty of Health Care, Tenri Health Care University; Institute for Advancement of Clinical and Translational Science, Kyoto University Hospital; Graduate School of Medicine, Kyoto University
| | - H Yamashiro
- Kyoto University Hospital, Kyoto, Japan; Kyoto University Hospital; Saitama Cancer Center; Hiroshima City Hospital; Toranomon Hospital; Gunma Prefectural Cancer Center; Jichi Medical University Hospital; National Cancer Center Hospital; Hyogo Cancer Center; Niigata Cancer Center Hospital; Kitasato University School of Medicine; Social Medical Corporation Hakuaikai, Sagara Hospital; Aichi Cancer Center; Clinical Cancer Center, National Kyushu Cancer Center; Tokyo Metropolitan Cancer and Infectious Diseases Centre, Komagome Hospital; Osaka National Hospital; National Hospital Organization Kure Medical Center; Institute for Advanced Biosciences, Keio University; Faculty of Medicine, University of Tsukuba; Keio University; Tohoku University Hospital and School of Medicine; Faculty of Health Care, Tenri Health Care University; Institute for Advancement of Clinical and Translational Science, Kyoto University Hospital; Graduate School of Medicine, Kyoto University
| | - M Sugimoto
- Kyoto University Hospital, Kyoto, Japan; Kyoto University Hospital; Saitama Cancer Center; Hiroshima City Hospital; Toranomon Hospital; Gunma Prefectural Cancer Center; Jichi Medical University Hospital; National Cancer Center Hospital; Hyogo Cancer Center; Niigata Cancer Center Hospital; Kitasato University School of Medicine; Social Medical Corporation Hakuaikai, Sagara Hospital; Aichi Cancer Center; Clinical Cancer Center, National Kyushu Cancer Center; Tokyo Metropolitan Cancer and Infectious Diseases Centre, Komagome Hospital; Osaka National Hospital; National Hospital Organization Kure Medical Center; Institute for Advanced Biosciences, Keio University; Faculty of Medicine, University of Tsukuba; Keio University; Tohoku University Hospital and School of Medicine; Faculty of Health Care, Tenri Health Care University; Institute for Advancement of Clinical and Translational Science, Kyoto University Hospital; Graduate School of Medicine, Kyoto University
| | - M Kondo
- Kyoto University Hospital, Kyoto, Japan; Kyoto University Hospital; Saitama Cancer Center; Hiroshima City Hospital; Toranomon Hospital; Gunma Prefectural Cancer Center; Jichi Medical University Hospital; National Cancer Center Hospital; Hyogo Cancer Center; Niigata Cancer Center Hospital; Kitasato University School of Medicine; Social Medical Corporation Hakuaikai, Sagara Hospital; Aichi Cancer Center; Clinical Cancer Center, National Kyushu Cancer Center; Tokyo Metropolitan Cancer and Infectious Diseases Centre, Komagome Hospital; Osaka National Hospital; National Hospital Organization Kure Medical Center; Institute for Advanced Biosciences, Keio University; Faculty of Medicine, University of Tsukuba; Keio University; Tohoku University Hospital and School of Medicine; Faculty of Health Care, Tenri Health Care University; Institute for Advancement of Clinical and Translational Science, Kyoto University Hospital; Graduate School of Medicine, Kyoto University
| | - Y Naito
- Kyoto University Hospital, Kyoto, Japan; Kyoto University Hospital; Saitama Cancer Center; Hiroshima City Hospital; Toranomon Hospital; Gunma Prefectural Cancer Center; Jichi Medical University Hospital; National Cancer Center Hospital; Hyogo Cancer Center; Niigata Cancer Center Hospital; Kitasato University School of Medicine; Social Medical Corporation Hakuaikai, Sagara Hospital; Aichi Cancer Center; Clinical Cancer Center, National Kyushu Cancer Center; Tokyo Metropolitan Cancer and Infectious Diseases Centre, Komagome Hospital; Osaka National Hospital; National Hospital Organization Kure Medical Center; Institute for Advanced Biosciences, Keio University; Faculty of Medicine, University of Tsukuba; Keio University; Tohoku University Hospital and School of Medicine; Faculty of Health Care, Tenri Health Care University; Institute for Advancement of Clinical and Translational Science, Kyoto University Hospital; Graduate School of Medicine, Kyoto University
| | - H Sasano
- Kyoto University Hospital, Kyoto, Japan; Kyoto University Hospital; Saitama Cancer Center; Hiroshima City Hospital; Toranomon Hospital; Gunma Prefectural Cancer Center; Jichi Medical University Hospital; National Cancer Center Hospital; Hyogo Cancer Center; Niigata Cancer Center Hospital; Kitasato University School of Medicine; Social Medical Corporation Hakuaikai, Sagara Hospital; Aichi Cancer Center; Clinical Cancer Center, National Kyushu Cancer Center; Tokyo Metropolitan Cancer and Infectious Diseases Centre, Komagome Hospital; Osaka National Hospital; National Hospital Organization Kure Medical Center; Institute for Advanced Biosciences, Keio University; Faculty of Medicine, University of Tsukuba; Keio University; Tohoku University Hospital and School of Medicine; Faculty of Health Care, Tenri Health Care University; Institute for Advancement of Clinical and Translational Science, Kyoto University Hospital; Graduate School of Medicine, Kyoto University
| | - T Inamoto
- Kyoto University Hospital, Kyoto, Japan; Kyoto University Hospital; Saitama Cancer Center; Hiroshima City Hospital; Toranomon Hospital; Gunma Prefectural Cancer Center; Jichi Medical University Hospital; National Cancer Center Hospital; Hyogo Cancer Center; Niigata Cancer Center Hospital; Kitasato University School of Medicine; Social Medical Corporation Hakuaikai, Sagara Hospital; Aichi Cancer Center; Clinical Cancer Center, National Kyushu Cancer Center; Tokyo Metropolitan Cancer and Infectious Diseases Centre, Komagome Hospital; Osaka National Hospital; National Hospital Organization Kure Medical Center; Institute for Advanced Biosciences, Keio University; Faculty of Medicine, University of Tsukuba; Keio University; Tohoku University Hospital and School of Medicine; Faculty of Health Care, Tenri Health Care University; Institute for Advancement of Clinical and Translational Science, Kyoto University Hospital; Graduate School of Medicine, Kyoto University
| | - S Morita
- Kyoto University Hospital, Kyoto, Japan; Kyoto University Hospital; Saitama Cancer Center; Hiroshima City Hospital; Toranomon Hospital; Gunma Prefectural Cancer Center; Jichi Medical University Hospital; National Cancer Center Hospital; Hyogo Cancer Center; Niigata Cancer Center Hospital; Kitasato University School of Medicine; Social Medical Corporation Hakuaikai, Sagara Hospital; Aichi Cancer Center; Clinical Cancer Center, National Kyushu Cancer Center; Tokyo Metropolitan Cancer and Infectious Diseases Centre, Komagome Hospital; Osaka National Hospital; National Hospital Organization Kure Medical Center; Institute for Advanced Biosciences, Keio University; Faculty of Medicine, University of Tsukuba; Keio University; Tohoku University Hospital and School of Medicine; Faculty of Health Care, Tenri Health Care University; Institute for Advancement of Clinical and Translational Science, Kyoto University Hospital; Graduate School of Medicine, Kyoto University
| | - M Toi
- Kyoto University Hospital, Kyoto, Japan; Kyoto University Hospital; Saitama Cancer Center; Hiroshima City Hospital; Toranomon Hospital; Gunma Prefectural Cancer Center; Jichi Medical University Hospital; National Cancer Center Hospital; Hyogo Cancer Center; Niigata Cancer Center Hospital; Kitasato University School of Medicine; Social Medical Corporation Hakuaikai, Sagara Hospital; Aichi Cancer Center; Clinical Cancer Center, National Kyushu Cancer Center; Tokyo Metropolitan Cancer and Infectious Diseases Centre, Komagome Hospital; Osaka National Hospital; National Hospital Organization Kure Medical Center; Institute for Advanced Biosciences, Keio University; Faculty of Medicine, University of Tsukuba; Keio University; Tohoku University Hospital and School of Medicine; Faculty of Health Care, Tenri Health Care University; Institute for Advancement of Clinical and Translational Science, Kyoto University Hospital; Graduate School of Medicine, Kyoto University
| |
Collapse
|
42
|
Kawabata H, Kakihara N, Atsuta H, Taga C, Nakamae C, Inamitsu H, Inoda H, Nishikawa M. Cooperation with Other Clinical Departments in Intervention of Palliative Care Team in Our Hospital. Ann Oncol 2013. [DOI: 10.1093/annonc/mdt460.5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
43
|
Kawabata H, Oda I, Suzuki H, Nonaka S, Yoshinaga S, Katai H, Taniguchi H, Kushima R, Saito Y. Bone metastasis from early gastric cancer following non-curative endoscopic submucosal dissection. World J Gastroenterol 2013; 19:5016-5020. [PMID: 23946610 PMCID: PMC3740435 DOI: 10.3748/wjg.v19.i30.5016] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/22/2013] [Revised: 05/14/2013] [Accepted: 06/04/2013] [Indexed: 02/06/2023] Open
Abstract
A 67-year-old male underwent endoscopic submucosal dissection (ESD) to treat early gastric cancer (EGC) in 2001. The lesion (50 mm × 25 mm diameter) was histologically diagnosed as poorly differentiated adenocarcinoma, with an ulcer finding. Although the tumor was confined to the mucosa with no evidence of lymphovascular involvement, the ESD was regarded as a non-curative resection due to the histological type, tumor size, and existence of an ulcer finding (as indicated by the 2010 Japanese gastric cancer treatment guidelines, ver. 3). Despite strong recommendation for subsequent gastrectomy, the patient refused surgery. An alternative follow-up routine was designed, which included five years of biannual clinical examinations to detect and measure serum tumor markers and perform visual assessment of recurrence by endoscopy and computed tomography scan after which the examinations were performed annually. The patient’s condition remained stable for eight years, until a complaint of back pain in 2010 prompted further clinical investigation. Bone scintigraphy indicated increased uptake. Histological examination of biopsy specimens taken from the lumbar spine revealed adenocarcinoma resembling the carcinoma cells from the EGC that had been treated previously by ESD, and which was consistent with immunohistochemical findings of gastrointestinal tract cancer. Thus, the diagnosis of bone metastasis from EGC was made. The reported rates of EGC recurrence in surgically resected cases range 1.4%-3.4%, but among these bone metastasis is very rare. To our knowledge, this is the first reported case of bone metastasis from EGC following a non-curative ESD and occurring after an eight-year disease-free interval.
Collapse
|
44
|
Pan X, Kawabata H, Hamilton M, Liu X. Patient characteristics associated with the initiation of novel oral anticoagulants versus warfarin in patients with atrial fibrillation. Eur Heart J 2013. [DOI: 10.1093/eurheartj/eht307.p543] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
45
|
Masuda N, Sato N, Higaki K, Kashiwaba M, Matsunami N, Takano T, Yamamura J, Kaneko K, Takahashi M, Ohno S, Fujisawa T, Tsuyuki S, Miyoshi Y, Ohtani S, Yamamoto Y, Bando H, Onoda T, Kawabata H, Morita S, Ueno T, Toi M. Abstract P1-14-08: A prospective multicenter randomized phase II neo-adjuvant study of 5-fluorouracil, epirubicin and cyclophosphamide (FEC) followed by docetaxel, cyclophosphamide and trastuzumab (TCH) versus TCH followed by FEC versus TCH alone, in patients (pts) with operable HER2 positive breast cancer: JBCRG-10 study. Cancer Res 2012. [DOI: 10.1158/0008-5472.sabcs12-p1-14-08] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: The current standard treatment of primary systemic therapy (PST) in HER2 positive breast cancer is anthracyclines (A) and/or taxanes combined with trastuzumab (H) which demonstrates high pathological complete response (pCR). The pCR is considered as a predictive marker of prognosis although results are slightly different depending on the hormone receptor status. We conducted a randomized phase II study to examine sequence of treatments and necessity of A in the treatments using TCH to improve outcome and reduce cardiac toxicity in Japanese HER2 positive pts.
Methods: Pts were treated with FEC (5FU 500 mg/m2, epirubicin 100 mg/m2, cyclophosphamide 500 mg/m2) and/or TCH (docetaxel 75 mg/m2, cyclophosphamide 600 mg/m2, H 6 mg/kg, loading by 8 mg) in 3 groups: 4 cycles of FEC followed by 4 cycles of TCH (A-TCH); 4 cycles of TCH followed by 4 cycles of FEC (TCH-A) or 6 cycles of TCH. An unplanned interim analysis was conducted due to one death by interstitial lung disease (ILD) in the A-TCH after completion of 8 cycles. The pCR results suggested A containing regimens did not exceed benefit from the current standard regimen. The study was continued by limiting allocation only to the TCH group considering efficacy and safety. The primary endpoint was pCR and secondary endpoints were overall response rate (ORR) and safety.
Results: A total of 103 pts were enrolled between Sep. 2009 and Sep. 2011; 21 pts in the A-TCH, 22 pts in the TCH-A and 60 pts in the TCH including pts enrolled after termination of random allocation. Characteristics of the 103 pts were; median age of 54 (range, 33–70), median tumor size of 35 mm (range, 12–80), 42 pts with N(+) (40.8%) and 62 ER positive pts (60.2%). Characteristics of pts in the TCH were; median age of 54.5 (range, 33–67), median tumor size of 35.5 mm (range, 12–80), 25 pts with N(+) (41.7%) and 34 ER positive pts (56.7%). No major difference was reported between groups treated with or without A. Per protocol population was 59 pts in the TCH and its pCR rate was 45.8% (95% CI, 32.2–59.3: ER negative, 61.5%; ER positive, 33.3%). ORR was 86.4% assessed by MRI or CT. Although it is an exploratory analysis, the pCR rate of A containing regimens was 39.0% (ER negative, 57.1%; ER positive, 29.6%). Adverse events ≥grade 3 were reported in 50 pts (48.5%). Reported ILD was in 5 pts (A-TCH, 1; TCH-A, 1; TCH, 3). The mean left ventricular ejection fraction (LVEF) decreased from 70.0% to 69.0% after treatment (A-TCH, 65.9%; TCH-A, 70.4%; TCH, 69.0%). Decrease of LVEF in the A-TCH was significant (p < 0.01).
Conclusion: The pCR rate of the TCH group was similar to previous reports on A including regimens. Although ILD had been occurred during the treatment containing the TCH, no other new safety issues were reported. We were not able to conclude preferable sequence of A and T since statistical power was not sufficient. However, the result of LVEF suggested TCH followed by A or TCH were preferable. Six cycles of TCH could be one of treatment options as a PST in HER2 positive breast cancer to exclude A. (UMIN000002365)
Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P1-14-08.
Collapse
Affiliation(s)
- N Masuda
- NHO Osaka National Hospital, Osaka, Japan; Niigata Cancer Center Hospital, Niigata, Japan; Hiroshima City Hospital, Hiroshima, Japan; Iwate Medical University, Morioka, Japan; Osaka Rosai Hospital, Sakai, Japan; Toranomon Hospital, Tokyo, Japan; Hokkaido Cancer Center, Sapporo, Japan; National Kyushu Cancer Center, Fukuoka, Japan; Gunma Prefectural Cancer Center, Ohta, Japan; Osaka Red Cross Hospital, Osaka, Japan; Hyogo College of Medicine, Nishinomiya, Japan; Kumamoto University Hospital, Kumamoto, Japan; University of Tsukuba, Faculty of Medicine, Tsukuba, Japan; Yokohama Asahi Central General Hospital, Yokohama, Japan; Yokohama City University Graduate School of Medicine and Medical Center, Yokohama, Japan; Kyoto University, Kyoto, Japan
| | - N Sato
- NHO Osaka National Hospital, Osaka, Japan; Niigata Cancer Center Hospital, Niigata, Japan; Hiroshima City Hospital, Hiroshima, Japan; Iwate Medical University, Morioka, Japan; Osaka Rosai Hospital, Sakai, Japan; Toranomon Hospital, Tokyo, Japan; Hokkaido Cancer Center, Sapporo, Japan; National Kyushu Cancer Center, Fukuoka, Japan; Gunma Prefectural Cancer Center, Ohta, Japan; Osaka Red Cross Hospital, Osaka, Japan; Hyogo College of Medicine, Nishinomiya, Japan; Kumamoto University Hospital, Kumamoto, Japan; University of Tsukuba, Faculty of Medicine, Tsukuba, Japan; Yokohama Asahi Central General Hospital, Yokohama, Japan; Yokohama City University Graduate School of Medicine and Medical Center, Yokohama, Japan; Kyoto University, Kyoto, Japan
| | - K Higaki
- NHO Osaka National Hospital, Osaka, Japan; Niigata Cancer Center Hospital, Niigata, Japan; Hiroshima City Hospital, Hiroshima, Japan; Iwate Medical University, Morioka, Japan; Osaka Rosai Hospital, Sakai, Japan; Toranomon Hospital, Tokyo, Japan; Hokkaido Cancer Center, Sapporo, Japan; National Kyushu Cancer Center, Fukuoka, Japan; Gunma Prefectural Cancer Center, Ohta, Japan; Osaka Red Cross Hospital, Osaka, Japan; Hyogo College of Medicine, Nishinomiya, Japan; Kumamoto University Hospital, Kumamoto, Japan; University of Tsukuba, Faculty of Medicine, Tsukuba, Japan; Yokohama Asahi Central General Hospital, Yokohama, Japan; Yokohama City University Graduate School of Medicine and Medical Center, Yokohama, Japan; Kyoto University, Kyoto, Japan
| | - M Kashiwaba
- NHO Osaka National Hospital, Osaka, Japan; Niigata Cancer Center Hospital, Niigata, Japan; Hiroshima City Hospital, Hiroshima, Japan; Iwate Medical University, Morioka, Japan; Osaka Rosai Hospital, Sakai, Japan; Toranomon Hospital, Tokyo, Japan; Hokkaido Cancer Center, Sapporo, Japan; National Kyushu Cancer Center, Fukuoka, Japan; Gunma Prefectural Cancer Center, Ohta, Japan; Osaka Red Cross Hospital, Osaka, Japan; Hyogo College of Medicine, Nishinomiya, Japan; Kumamoto University Hospital, Kumamoto, Japan; University of Tsukuba, Faculty of Medicine, Tsukuba, Japan; Yokohama Asahi Central General Hospital, Yokohama, Japan; Yokohama City University Graduate School of Medicine and Medical Center, Yokohama, Japan; Kyoto University, Kyoto, Japan
| | - N Matsunami
- NHO Osaka National Hospital, Osaka, Japan; Niigata Cancer Center Hospital, Niigata, Japan; Hiroshima City Hospital, Hiroshima, Japan; Iwate Medical University, Morioka, Japan; Osaka Rosai Hospital, Sakai, Japan; Toranomon Hospital, Tokyo, Japan; Hokkaido Cancer Center, Sapporo, Japan; National Kyushu Cancer Center, Fukuoka, Japan; Gunma Prefectural Cancer Center, Ohta, Japan; Osaka Red Cross Hospital, Osaka, Japan; Hyogo College of Medicine, Nishinomiya, Japan; Kumamoto University Hospital, Kumamoto, Japan; University of Tsukuba, Faculty of Medicine, Tsukuba, Japan; Yokohama Asahi Central General Hospital, Yokohama, Japan; Yokohama City University Graduate School of Medicine and Medical Center, Yokohama, Japan; Kyoto University, Kyoto, Japan
| | - T Takano
- NHO Osaka National Hospital, Osaka, Japan; Niigata Cancer Center Hospital, Niigata, Japan; Hiroshima City Hospital, Hiroshima, Japan; Iwate Medical University, Morioka, Japan; Osaka Rosai Hospital, Sakai, Japan; Toranomon Hospital, Tokyo, Japan; Hokkaido Cancer Center, Sapporo, Japan; National Kyushu Cancer Center, Fukuoka, Japan; Gunma Prefectural Cancer Center, Ohta, Japan; Osaka Red Cross Hospital, Osaka, Japan; Hyogo College of Medicine, Nishinomiya, Japan; Kumamoto University Hospital, Kumamoto, Japan; University of Tsukuba, Faculty of Medicine, Tsukuba, Japan; Yokohama Asahi Central General Hospital, Yokohama, Japan; Yokohama City University Graduate School of Medicine and Medical Center, Yokohama, Japan; Kyoto University, Kyoto, Japan
| | - J Yamamura
- NHO Osaka National Hospital, Osaka, Japan; Niigata Cancer Center Hospital, Niigata, Japan; Hiroshima City Hospital, Hiroshima, Japan; Iwate Medical University, Morioka, Japan; Osaka Rosai Hospital, Sakai, Japan; Toranomon Hospital, Tokyo, Japan; Hokkaido Cancer Center, Sapporo, Japan; National Kyushu Cancer Center, Fukuoka, Japan; Gunma Prefectural Cancer Center, Ohta, Japan; Osaka Red Cross Hospital, Osaka, Japan; Hyogo College of Medicine, Nishinomiya, Japan; Kumamoto University Hospital, Kumamoto, Japan; University of Tsukuba, Faculty of Medicine, Tsukuba, Japan; Yokohama Asahi Central General Hospital, Yokohama, Japan; Yokohama City University Graduate School of Medicine and Medical Center, Yokohama, Japan; Kyoto University, Kyoto, Japan
| | - K Kaneko
- NHO Osaka National Hospital, Osaka, Japan; Niigata Cancer Center Hospital, Niigata, Japan; Hiroshima City Hospital, Hiroshima, Japan; Iwate Medical University, Morioka, Japan; Osaka Rosai Hospital, Sakai, Japan; Toranomon Hospital, Tokyo, Japan; Hokkaido Cancer Center, Sapporo, Japan; National Kyushu Cancer Center, Fukuoka, Japan; Gunma Prefectural Cancer Center, Ohta, Japan; Osaka Red Cross Hospital, Osaka, Japan; Hyogo College of Medicine, Nishinomiya, Japan; Kumamoto University Hospital, Kumamoto, Japan; University of Tsukuba, Faculty of Medicine, Tsukuba, Japan; Yokohama Asahi Central General Hospital, Yokohama, Japan; Yokohama City University Graduate School of Medicine and Medical Center, Yokohama, Japan; Kyoto University, Kyoto, Japan
| | - M Takahashi
- NHO Osaka National Hospital, Osaka, Japan; Niigata Cancer Center Hospital, Niigata, Japan; Hiroshima City Hospital, Hiroshima, Japan; Iwate Medical University, Morioka, Japan; Osaka Rosai Hospital, Sakai, Japan; Toranomon Hospital, Tokyo, Japan; Hokkaido Cancer Center, Sapporo, Japan; National Kyushu Cancer Center, Fukuoka, Japan; Gunma Prefectural Cancer Center, Ohta, Japan; Osaka Red Cross Hospital, Osaka, Japan; Hyogo College of Medicine, Nishinomiya, Japan; Kumamoto University Hospital, Kumamoto, Japan; University of Tsukuba, Faculty of Medicine, Tsukuba, Japan; Yokohama Asahi Central General Hospital, Yokohama, Japan; Yokohama City University Graduate School of Medicine and Medical Center, Yokohama, Japan; Kyoto University, Kyoto, Japan
| | - S Ohno
- NHO Osaka National Hospital, Osaka, Japan; Niigata Cancer Center Hospital, Niigata, Japan; Hiroshima City Hospital, Hiroshima, Japan; Iwate Medical University, Morioka, Japan; Osaka Rosai Hospital, Sakai, Japan; Toranomon Hospital, Tokyo, Japan; Hokkaido Cancer Center, Sapporo, Japan; National Kyushu Cancer Center, Fukuoka, Japan; Gunma Prefectural Cancer Center, Ohta, Japan; Osaka Red Cross Hospital, Osaka, Japan; Hyogo College of Medicine, Nishinomiya, Japan; Kumamoto University Hospital, Kumamoto, Japan; University of Tsukuba, Faculty of Medicine, Tsukuba, Japan; Yokohama Asahi Central General Hospital, Yokohama, Japan; Yokohama City University Graduate School of Medicine and Medical Center, Yokohama, Japan; Kyoto University, Kyoto, Japan
| | - T Fujisawa
- NHO Osaka National Hospital, Osaka, Japan; Niigata Cancer Center Hospital, Niigata, Japan; Hiroshima City Hospital, Hiroshima, Japan; Iwate Medical University, Morioka, Japan; Osaka Rosai Hospital, Sakai, Japan; Toranomon Hospital, Tokyo, Japan; Hokkaido Cancer Center, Sapporo, Japan; National Kyushu Cancer Center, Fukuoka, Japan; Gunma Prefectural Cancer Center, Ohta, Japan; Osaka Red Cross Hospital, Osaka, Japan; Hyogo College of Medicine, Nishinomiya, Japan; Kumamoto University Hospital, Kumamoto, Japan; University of Tsukuba, Faculty of Medicine, Tsukuba, Japan; Yokohama Asahi Central General Hospital, Yokohama, Japan; Yokohama City University Graduate School of Medicine and Medical Center, Yokohama, Japan; Kyoto University, Kyoto, Japan
| | - S Tsuyuki
- NHO Osaka National Hospital, Osaka, Japan; Niigata Cancer Center Hospital, Niigata, Japan; Hiroshima City Hospital, Hiroshima, Japan; Iwate Medical University, Morioka, Japan; Osaka Rosai Hospital, Sakai, Japan; Toranomon Hospital, Tokyo, Japan; Hokkaido Cancer Center, Sapporo, Japan; National Kyushu Cancer Center, Fukuoka, Japan; Gunma Prefectural Cancer Center, Ohta, Japan; Osaka Red Cross Hospital, Osaka, Japan; Hyogo College of Medicine, Nishinomiya, Japan; Kumamoto University Hospital, Kumamoto, Japan; University of Tsukuba, Faculty of Medicine, Tsukuba, Japan; Yokohama Asahi Central General Hospital, Yokohama, Japan; Yokohama City University Graduate School of Medicine and Medical Center, Yokohama, Japan; Kyoto University, Kyoto, Japan
| | - Y Miyoshi
- NHO Osaka National Hospital, Osaka, Japan; Niigata Cancer Center Hospital, Niigata, Japan; Hiroshima City Hospital, Hiroshima, Japan; Iwate Medical University, Morioka, Japan; Osaka Rosai Hospital, Sakai, Japan; Toranomon Hospital, Tokyo, Japan; Hokkaido Cancer Center, Sapporo, Japan; National Kyushu Cancer Center, Fukuoka, Japan; Gunma Prefectural Cancer Center, Ohta, Japan; Osaka Red Cross Hospital, Osaka, Japan; Hyogo College of Medicine, Nishinomiya, Japan; Kumamoto University Hospital, Kumamoto, Japan; University of Tsukuba, Faculty of Medicine, Tsukuba, Japan; Yokohama Asahi Central General Hospital, Yokohama, Japan; Yokohama City University Graduate School of Medicine and Medical Center, Yokohama, Japan; Kyoto University, Kyoto, Japan
| | - S Ohtani
- NHO Osaka National Hospital, Osaka, Japan; Niigata Cancer Center Hospital, Niigata, Japan; Hiroshima City Hospital, Hiroshima, Japan; Iwate Medical University, Morioka, Japan; Osaka Rosai Hospital, Sakai, Japan; Toranomon Hospital, Tokyo, Japan; Hokkaido Cancer Center, Sapporo, Japan; National Kyushu Cancer Center, Fukuoka, Japan; Gunma Prefectural Cancer Center, Ohta, Japan; Osaka Red Cross Hospital, Osaka, Japan; Hyogo College of Medicine, Nishinomiya, Japan; Kumamoto University Hospital, Kumamoto, Japan; University of Tsukuba, Faculty of Medicine, Tsukuba, Japan; Yokohama Asahi Central General Hospital, Yokohama, Japan; Yokohama City University Graduate School of Medicine and Medical Center, Yokohama, Japan; Kyoto University, Kyoto, Japan
| | - Y Yamamoto
- NHO Osaka National Hospital, Osaka, Japan; Niigata Cancer Center Hospital, Niigata, Japan; Hiroshima City Hospital, Hiroshima, Japan; Iwate Medical University, Morioka, Japan; Osaka Rosai Hospital, Sakai, Japan; Toranomon Hospital, Tokyo, Japan; Hokkaido Cancer Center, Sapporo, Japan; National Kyushu Cancer Center, Fukuoka, Japan; Gunma Prefectural Cancer Center, Ohta, Japan; Osaka Red Cross Hospital, Osaka, Japan; Hyogo College of Medicine, Nishinomiya, Japan; Kumamoto University Hospital, Kumamoto, Japan; University of Tsukuba, Faculty of Medicine, Tsukuba, Japan; Yokohama Asahi Central General Hospital, Yokohama, Japan; Yokohama City University Graduate School of Medicine and Medical Center, Yokohama, Japan; Kyoto University, Kyoto, Japan
| | - H Bando
- NHO Osaka National Hospital, Osaka, Japan; Niigata Cancer Center Hospital, Niigata, Japan; Hiroshima City Hospital, Hiroshima, Japan; Iwate Medical University, Morioka, Japan; Osaka Rosai Hospital, Sakai, Japan; Toranomon Hospital, Tokyo, Japan; Hokkaido Cancer Center, Sapporo, Japan; National Kyushu Cancer Center, Fukuoka, Japan; Gunma Prefectural Cancer Center, Ohta, Japan; Osaka Red Cross Hospital, Osaka, Japan; Hyogo College of Medicine, Nishinomiya, Japan; Kumamoto University Hospital, Kumamoto, Japan; University of Tsukuba, Faculty of Medicine, Tsukuba, Japan; Yokohama Asahi Central General Hospital, Yokohama, Japan; Yokohama City University Graduate School of Medicine and Medical Center, Yokohama, Japan; Kyoto University, Kyoto, Japan
| | - T Onoda
- NHO Osaka National Hospital, Osaka, Japan; Niigata Cancer Center Hospital, Niigata, Japan; Hiroshima City Hospital, Hiroshima, Japan; Iwate Medical University, Morioka, Japan; Osaka Rosai Hospital, Sakai, Japan; Toranomon Hospital, Tokyo, Japan; Hokkaido Cancer Center, Sapporo, Japan; National Kyushu Cancer Center, Fukuoka, Japan; Gunma Prefectural Cancer Center, Ohta, Japan; Osaka Red Cross Hospital, Osaka, Japan; Hyogo College of Medicine, Nishinomiya, Japan; Kumamoto University Hospital, Kumamoto, Japan; University of Tsukuba, Faculty of Medicine, Tsukuba, Japan; Yokohama Asahi Central General Hospital, Yokohama, Japan; Yokohama City University Graduate School of Medicine and Medical Center, Yokohama, Japan; Kyoto University, Kyoto, Japan
| | - H Kawabata
- NHO Osaka National Hospital, Osaka, Japan; Niigata Cancer Center Hospital, Niigata, Japan; Hiroshima City Hospital, Hiroshima, Japan; Iwate Medical University, Morioka, Japan; Osaka Rosai Hospital, Sakai, Japan; Toranomon Hospital, Tokyo, Japan; Hokkaido Cancer Center, Sapporo, Japan; National Kyushu Cancer Center, Fukuoka, Japan; Gunma Prefectural Cancer Center, Ohta, Japan; Osaka Red Cross Hospital, Osaka, Japan; Hyogo College of Medicine, Nishinomiya, Japan; Kumamoto University Hospital, Kumamoto, Japan; University of Tsukuba, Faculty of Medicine, Tsukuba, Japan; Yokohama Asahi Central General Hospital, Yokohama, Japan; Yokohama City University Graduate School of Medicine and Medical Center, Yokohama, Japan; Kyoto University, Kyoto, Japan
| | - S Morita
- NHO Osaka National Hospital, Osaka, Japan; Niigata Cancer Center Hospital, Niigata, Japan; Hiroshima City Hospital, Hiroshima, Japan; Iwate Medical University, Morioka, Japan; Osaka Rosai Hospital, Sakai, Japan; Toranomon Hospital, Tokyo, Japan; Hokkaido Cancer Center, Sapporo, Japan; National Kyushu Cancer Center, Fukuoka, Japan; Gunma Prefectural Cancer Center, Ohta, Japan; Osaka Red Cross Hospital, Osaka, Japan; Hyogo College of Medicine, Nishinomiya, Japan; Kumamoto University Hospital, Kumamoto, Japan; University of Tsukuba, Faculty of Medicine, Tsukuba, Japan; Yokohama Asahi Central General Hospital, Yokohama, Japan; Yokohama City University Graduate School of Medicine and Medical Center, Yokohama, Japan; Kyoto University, Kyoto, Japan
| | - T Ueno
- NHO Osaka National Hospital, Osaka, Japan; Niigata Cancer Center Hospital, Niigata, Japan; Hiroshima City Hospital, Hiroshima, Japan; Iwate Medical University, Morioka, Japan; Osaka Rosai Hospital, Sakai, Japan; Toranomon Hospital, Tokyo, Japan; Hokkaido Cancer Center, Sapporo, Japan; National Kyushu Cancer Center, Fukuoka, Japan; Gunma Prefectural Cancer Center, Ohta, Japan; Osaka Red Cross Hospital, Osaka, Japan; Hyogo College of Medicine, Nishinomiya, Japan; Kumamoto University Hospital, Kumamoto, Japan; University of Tsukuba, Faculty of Medicine, Tsukuba, Japan; Yokohama Asahi Central General Hospital, Yokohama, Japan; Yokohama City University Graduate School of Medicine and Medical Center, Yokohama, Japan; Kyoto University, Kyoto, Japan
| | - M Toi
- NHO Osaka National Hospital, Osaka, Japan; Niigata Cancer Center Hospital, Niigata, Japan; Hiroshima City Hospital, Hiroshima, Japan; Iwate Medical University, Morioka, Japan; Osaka Rosai Hospital, Sakai, Japan; Toranomon Hospital, Tokyo, Japan; Hokkaido Cancer Center, Sapporo, Japan; National Kyushu Cancer Center, Fukuoka, Japan; Gunma Prefectural Cancer Center, Ohta, Japan; Osaka Red Cross Hospital, Osaka, Japan; Hyogo College of Medicine, Nishinomiya, Japan; Kumamoto University Hospital, Kumamoto, Japan; University of Tsukuba, Faculty of Medicine, Tsukuba, Japan; Yokohama Asahi Central General Hospital, Yokohama, Japan; Yokohama City University Graduate School of Medicine and Medical Center, Yokohama, Japan; Kyoto University, Kyoto, Japan
| |
Collapse
|
46
|
Niihata K, Tomosugi N, Uehata T, Shoji T, Mitsumoto K, Shimizu M, Kawabata H, Sakaguchi Y, Suzuki A, Hayashi T, Okada N, Isaka Y, Rakugi H, Tsubakihara Y. Serum hepcidin-25 levels predict the progression of renal anemia in patients with non-dialysis chronic kidney disease. Nephrol Dial Transplant 2012; 27:4378-85; discussion 4384-5. [DOI: 10.1093/ndt/gfs322] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023] Open
|
47
|
Miura D, Hanaoka M, Shimomura A, Iwatani T, Kawabata H, Fujii T. 442 Are There Any Differences of Biomarker Changes in Short Term Neoadjuvant Ais (Exemestane Vs. Letrozole)? Eur J Cancer 2012. [DOI: 10.1016/s0959-8049(12)70508-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
48
|
Sato R, Fujiya M, Watari J, Ueno N, Moriichi K, Kashima S, Maeda S, Ando K, Kawabata H, Sugiyama R, Nomura Y, Nata T, Itabashi K, Inaba Y, Okamoto K, Mizukami Y, Saitoh Y, Kohgo Y. The diagnostic accuracy of high-resolution endoscopy, autofluorescence imaging and narrow-band imaging for differentially diagnosing colon adenoma. Endoscopy 2011; 43:862-8. [PMID: 21732270 DOI: 10.1055/s-0030-1256510] [Citation(s) in RCA: 47] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
Abstract
BACKGROUND AND STUDY AIMS Conventional colonoscopy can result in unnecessary biopsy or endoscopic resection due to its inability to distinguish adenomas from hyperplastic polyps. This study therefore evaluated the efficacy of high-resolution endoscopy (HRE), autofluorescence imaging (AFI), and narrow-band imaging (NBI) in discriminating colon adenoma from hyperplastic polyps. PATIENTS AND METHODS This was a prospective multicenter study in patients undergoing AFI and NBI examinations. HRE, AFI, and NBI images were classified into two groups based on morphological characteristics, the predominant color intensities, and the visibility of meshed capillary vessels, respectively. Each of the endoscopic photographs were independently evaluated by a single endoscopist. The images were then assessed by three specialists and three residents, the latter having performed < 500 colonoscopies and < 30 NBI and AFI examinations. Diagnostic test statistics were calculated to compare the accuracy in differentiating colon adenoma from hyperplastic polyps for each method. RESULTS A total of 183 patients were enrolled in the study and 339 adenomas and 85 hyperplastic polyps were identified. AFI and NBI could distinguish adenoma from hyperplastic polyps with an accuracy of 84.9 % and 88.4 %, respectively, whereas HRE exhibited an accuracy of 75.9 %. In the 358 lesions in which the AFI diagnosis was consistent with that of NBI, the accuracy, sensitivity, and specificity were high, at 91.9 %, 92.7 %, and 92.9 %, respectively. During the study comparing specialists and residents, AFI and NBI dramatically improved the diagnostic accuracy of residents from 69.1 % to 86.1 % and 84.7 %, respectively. CONCLUSIONS Both AFI and NBI are considered to be feasible tools that can discriminate colon adenoma from hyperplastic polyps, and their use may be particularly beneficial for less-experienced endoscopists.
Collapse
Affiliation(s)
- R Sato
- Internal Medicine, Engaru-Kosei General Hospital, Asahikawa, Japan
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
49
|
Miura Y, Naito Y, Shimomura A, Iwatani T, Miura D, Kawabata H, Takano T. 3059 POSTER The Safety of Chemotherapy for Breast Cancer Patients With Hepatitis C Virus Infection. Eur J Cancer 2011. [DOI: 10.1016/s0959-8049(11)71132-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
50
|
Ishibashi M, Naito Y, Miura Y, Takano T, Kishi K, Kitagawa H, Miura D, Kawabata H, Udagawa H. 1308 POSTER Paclitaxel-related Interstitial Lung Disease – Implication of Mediastinal Lymphadenopathy. Eur J Cancer 2011. [DOI: 10.1016/s0959-8049(11)70882-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|